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Abstract
It is well-established that undernutrition during pregnancy increases offsprings risk of
disease in later life. Studies have found that maternal protein restriction during rodent
gestation programmes premature hypertrophic growth and decreased mitotic index of
cardiomyocytes, as well as impaired contractile ability of the heart. All of these are
predisposing factors to cardiovascular disease. To date, few studies have focused on
the underlying mechanisms that lead to such alterations in the structure and function
of the cardiovascular system. This study aimed to investigate if protein deficiency
during gestation impacts upon cardiomyocyte proliferation, and glucose uptake and
transport in vitro, and if programming effects can be demonstrated in culture.
Methods. Trial 1: Ten pregnant wistar rats were fed either a control or low protein
(MLP) diet throughout gestation. Pups were culled on the day of birth and hearts were
taken to isolate cardiomyocytes. After 10 days in culture (baseline) some
cardiomyocytes were treated with 100nM and 10ǋM of dexamethasone (Dex) for 48
hours (Day 2). Both untreated and Dex treated cultures were analysed for proliferation
and differentiation rates, and glucose uptake. Trial 2: Gestational diet and culturing of
cardiomyocyte cells was the same as in trial one. Cultures were treated with 10nM and
100nM Dex and analysed at the same time points for proliferation and differentiation
rates, cell apoptosis and mRNA expression of glucose transporters. Results. In trial
one, MLP diet increased day 2 binucleation. High concentrations of Dex increased
insulin stimulated glucose uptake in MLP neonatal cardiomyocytes indicating they had
an increased sensitivity to glucocorticoids. In trial two, Dex treatment decreased
expression of GLUT 4 and increased expression of glucocorticoid receptor (GR) mRNA.
Conclusion. Results indicate possible remodelling of the heart in rat offspring
exposed to MLP diet in utero, but it remains unclear as to what mechanism underpins
MLP cultures increased sensitivity to glucocorticoids. There were some similarities to
the findings of in vivo studies, but responses varied between trials. This indicates that
iii
cell culture is unlikely to become a viable alternative model, but it is a useful tool for
exploring focused mechanisms of fetal programming.
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Introduction
1.1 Cardiovascular Disease (CVD)
Cardiovascular diseases (CVD) are diseases of the heart and circulatory system. They
are the UKs biggest cause of death, responsible for 30% of premature deaths in men,
and 22% in women in 2006. This is estimated to cost the UKs economy around £30.7
billion a year, putting a huge strain on the nations health system (British Heart
Foundation (BHF) Coronary Heart Disease Statistics, 2008). One of the main forms of
CVD is coronary heart disease (CHD), which accounts for approximately 19% of
deaths in men and 14% in women, and is on the rise (BHF, Coronary Heart Disease
Statistics, 2008). Stroke is another outcome of CVD accounting for a quarter of CVD
related deaths.
CHD occurs when there is occlusion of the coronary artery by an atherosclerotic
plaque consisting of LDL cholesterol (British Nutrition Foundation, 1993, Moss et al.,
1999). This obstructs the blood supply to the heart, leading to a deficiency of nutrients
and oxygen to tissue, and impairing contractile ability (British Nutrition Foundation,
1993).
Stroke is a cerebrovascular disease, and occurs when there is a disturbance of the
blood supply to the brain (Frayn & Stanner, 2005). There are two types, the first is
ischemic stroke, where a blood clot forms in the heart, becomes dislodged and travels
to the brain where it blocks an artery. The reduced blood supply may lead to
permanent damage to the brain. The second is known as haemorrhagic stroke, where
a blood vessel ruptures in the brain, releasing blood. Increased blood pressure is a
common risk factor for developing this type of stroke (Frayn & Stanner, 2005).
21.1.1 Onset of CHD
There are three main events that lead to occlusion of arteries, injury to the coronary
artery wall, atherosclerosis, and thrombosis. (British Nutrition Foundation, 1993,
Rifkind, 1987). Normally, the lumen of the artery can respond to minor injuries/lesions
caused from blood flow, but repeated wear from damaged lipid particles and free
radicals can lead to more severe injuries. To repair the artery wall, platelets adhere to
the damaged area, which causes a set of reactions to increase cell multiplication. This
leads to a thickening of the inner wall due to collagen production and deposition of
dead cell material. Thickening of the wall is increased further by scavenging
macrophages removing oxidised lipid (LDL) particles (British Nutrition Foundation,
1993, Frayn & Stanner, 2005, Brown & Goldstein, 1996). This is not a regulated
process so macrophages can take up large amounts of lipid, and then become
overloaded (British Nutrition Foundation, 1993, Frayn & Stanner, 2005). These
overloaded macrophages form foam cells, which accumulate in the artery forming a
yellow raised spot, which later develops into fatty streaks (Frayn & Stanner, 2005). A
blood clotting mechanism is now triggered and white blood cells, such as T-
lymphocytes and blood monocytes attach to the atherosclerotic region (British
Nutrition Foundation, 1993, Frayn & Stanner, 2005). Monocytes differentiate into
macrophages and increase the uptake of oxidised LDL. Platelets then attach to the
lesion and growth factors encourage smooth muscle proliferation on the artery walls
forming a fibrous cap. This can then become hard and protrude into the artery,
blocking blood flow (British Nutrition Foundation, 1993, Frayn & Stanner, 2005). Some
plaques become weak and unstable, and can rupture releasing the contents of the
lesion. The coagulation cascade leads to a thrombus being formed, which leads to the
already narrowed artery being further blocked. Some plaques can completely block the
artery leading to myocardial infarction (British Nutrition Foundation, 1993, Frayn &
Stanner, 2005).
3There are many factors attributing to increased risk of developing CVD. Some are
uncontrollable by an individual such as genetic inheritance, as well as race, gender
and age. Other risk factors are due to an individuals life style choice, such as, poor
diet, lack of exercise, excessive alcohol consumption and smoking (BHF Coronary
Heart Disease Statistics, 2008, Brown & Goldstein, 1996).
1.1.2 Uncontrollable/Background Risk Factors
CVD are diseases associated with old age, but are the most common causes of
premature deaths (death before 75 years) in Britain (BHF, Coronary Heart Disease
Statistics, 2008). In the UK, the Scottish population and Northern England have higher
mortality due to CHD in comparison to Southern areas (BHF, Coronary Heart Disease
Statistics, 2008). The North-South divide in health was also noted in a study
completed by Barker in the early 1900s, where death rates due to low birth weight (a
precursor of CVD) were higher in Northern industrial towns (Barker, 1997). This is
partly due to socio-economic differences across the UK. In the late 1990s, the BHF
estimated that due to social class inequalities, 5000 working class lives were lost each
year amongst men aged 20-64 years.
This is not just a problem affecting the UK, but also various ethnic groups living in the
UK, as well as populations internationally (BHF Coronary Heart Disease Statistics,
2008). Countries in Eastern and Central Europe generally have higher death rates
from CHD in comparison to the UK. The Ukraine, for example, has experienced an
increase in mortality from CHD between the years 1990 and 2000 (BHF Coronary
Heart Disease Statistics, 2008). Ethnic groups, such as South Asians living in the UK,
are more predisposed to develop heart problems (BHF Coronary Heart Disease
Statistics, 2008), and have a higher premature death rates. This is similar amongst
4Pakistani women who have 146% higher death rate, and Bangladeshi men, who have
112% higher death rate compared to the average for people living in the England and
Wales (BHF Coronary Heart Disease Statistics, 2008).
1.1.3 Controllable/Lifestyle Risk Factors
Lifestyle choices, such as poor diet and lack of exercise increase the risk of developing
coronary vascular diseases, as well as other life threatening conditions including
diabetes and obesity. According to the BHF only 13% of British men, and 15% of
women eat their daily recommended five portions of fruit and vegetables, and most of
the population are consuming more than the recommended levels of saturated fat
(BHF, Coronary Heart Disease Statistics, 2008). In 2002, the World Health
Organisation suggested that due to low fruit and vegetable consumption (<600g/day)
approximately 30% of the Western population suffered with CHD, and 20% with
strokes. In 2006, 24% of the UKs population was classified as obese, with 32% of
women and 43% of men being overweight (BHF, Coronary Heart Disease Statistics,
2008). Obesity is defined using the body mass index (BMI) measure. To be classified
as obese an individual has to have a BMI of over 30. This is associated with high blood
pressure, increased plasma insulin and cholesterol levels, all of which increase the
possibility of developing CHD (British Nutrition Foundation, 1993, Brown & Goldstein,
1996).
In 2006, a UK health survey showed that only 40% of men and 28% of woman
achieved the recommended amount of exercise of five 30 minute sessions of aerobic
activity a week (BHF Coronary Heart Disease Statistics, 2008). It is also becoming a
common problem in the under 15s where approximately only 65% are fulfilling the
recommended quota. Figure 1.1 illustrates the effects that low levels of exercise can
5have on an individuals risk of developing CVD. Smokers increase their risk of
developing CHD by 60% in comparison to non-smokers. It is estimated that smoking
caused approximately 25,000 deaths from coronary heart disease alone in 2000 (BHF
Coronary Heart Disease Statistics, 2008). Smoking leads to peripheral vascular
disease (PVD), which is narrowing of peripheral arteries in areas other than the main
blood supply, such as the leg. Smoking leads to various physiological responses
detailed in Figure 1.2, which are similar to those seen in CHD. In severe cases this can
lead to loss of limbs (Frayn & Stanner, 2005).
6Figure 1.1  Consequences of poor or lack of exercise that can lead to cardiac failure
(Modified from British Nutrition Foundation, 1993)
Figure 1.2 - Consequences of smoking that can lead to cardiac failure
(Modified from British Nutrition Foundation, 1993)
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71.2 Hypertension
High blood pressure is a symptom-less illness affecting 31% of men and 28% of
women in England in 2006 (BHF Coronary Heart Statistics, 2008, Levick, 2000). In 40-
69 year old adults, each 10mmHg in diastolic blood pressure and 20mmHg increase in
systolic blood pressure doubles the risk of death from CHD (BHF Coronary Heart
Statistics, 2008). The World Health Report in 2002 stated that 50% of CHD cases and
22% of heart attacks are caused by hypertension due to an increase in systolic blood
pressure (Interheart, BHF Coronary Heart Statistics, 2008).
Blood pressure is dependent on the equilibrium between cardiac output and peripheral
resistance (Levick, 2000). Hypertension is defined as chronic, usually progressive,
raised arterial pressure, and is normally diagnosed as a resting pressure in patients
under 50 years of 140/90mmHg. In patients over 50 it is diagnosed when pressure
rises above 160/95mmHg (Levick, 2000, BHF Coronary Heart Statistics, 2008). There
are two types of hypertension, primary and secondary. Primary, also known as
essential hypertension, accounts for approximately 90% of cases that have no
definable cause. Development of primary hypertension can be slow or rapid, and if left
untreated can lead to various diseases including cardiac failure, cerebral damage and
renal damage. Secondary (non-essential) hypertension is quite uncommon and
includes Conns syndrome and renal artery stenosis (Levick, 2000).
An individual with high blood pressure experiences moderately normal cardiac output
with raised peripheral resistance, but in the early stages of hypertension development,
cardiac output is raised and peripheral resistance is normal (Levick, 2000, Langley-
Evans et al., 1994). If the problem remains untreated it can then affect other organs
including the kidneys. In the heart this can lead to hypertrophic growth of the smooth
muscle, raising blood pressure as the inner walls of the arteries begin to narrow.
8Eventually it will lead to compensatory hypertrophy of the left ventricle wall due the
heart having to work harder (Levick, 2000).
1.3 Fetal Programming
It is understood that pregnant women should eat a balanced diet including all the
essential food groups, minerals and vitamins (macro- and micro-nutrients). It is not so
well known by the general public though, that small alterations in dietary intake can
have a lasting effect on offspring in later life.
Fetal programming, also known as the Fetal Origins of Health and Disease, refers to
the theory that the in utero environment influences the growth and development of
the fetus. Evidence suggests that maternal influences such as poor nutrition and
stress during fetal development, lead to irreversible adaptations in the structure and
function of organs, which predispose the offspring to the onset of various diseases in
later life (Godfrey & Barker, 2000). This hypothesis was first defined by Barker in
1980s and has since been researched extensively using both epidemiological and
experimental approaches. For this study, nutritional insults to the fetus during
development, and the effects these have on risk of coronary heart disease are the
main areas of interest.
The hypothesis evolved from evidence that low birth weight, high placental weight and
infant head circumference at birth are related to offspring developing cardiovascular
problems in later life (Campbell et al., 1996, Godfrey et al., 1996, Godfrey & Barker,
2000). Low birth weight is also an indicator to the onset of other disorders including
hypertension, glucose intolerance and diabetes (Nyirenda et al., 1998).
9Barkers 1986 Hertfordshire study found that small birth size was associated with
increased incidence of CVD related deaths, as well as type II diabetes and insulin
resistance. The study investigated interactions between intrauterine environment,
adult diet and lifestyle, and disease onset. As well as low birth weight associated with
increased risk of disease, it was also noted that birth weight and weight at one year
was positively associated with BMI and fat mass.
Low birth weight also increases an individuals chance of developing hypertension
(Campbell et al., 1996), and is thought that adult blood pressure is set in utero. The
Aberdeen pregnancy study (Campbell et al., 1996) monitored women at seven months
of gestation, and recorded food consumption during a one week period. For the first
time, a link between maternal consumption of animal proteins and carbohydrates, and
offspring low birth weight was found. Higher maternal protein intake led to low birth
weight. Low protein and high carbohydrate intake was associated with increased blood
pressure and low placental weight. High protein and low carbohydrate intake was also
predictive of hypertension in the offspring. Godfrey et al. (1996) found in a study of
Southampton women that the same nutrients were associated with markers of fetal
growth. An increased carbohydrate intake in early pregnancy was predictive of the
offspring having low placental and birth weight, and the same was seen in dairy and
meat protein restricted females in late gestation.
Another study that found a link between nutritional intake during pregnancy and
offsprings later risk of various diseases, and is one of the main studies that
contributed to the development of the fetal origins hypothesis, was the WWII Dutch
famine study completed by Roseboom et al., 2001. Previous to the wartime famine the
population were well nourished, with an average energy intake of approximately 2000
calories a day. Due to a reduction of war time rations, calorie intake dropped to
between 400-800 calories a day for a period of six months. Remarkably, women still
managed to conceive and give birth during this time. During the famine, data was
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collected on pregnant women whose babies were exposed during early, mid and late
gestation. Offspring were then followed up later in life for analysis of their health. It
was found that offspring exposed to famine specifically during the first trimester of
pregnancy appeared to have a higher risk of CHD in later life (Roseboom et al., 2001)
despite being of normal to high birth weight.
As well as these studies corroborating the proposal that maternal undernutrition leads
to low birth weight and later onset of cardiovascular problems, they also highlighted
that time of insult determines the effects it will have on the offspring. If the fetus is
exposed to nutritional deficiencies during a critical window of development then
different organs will be affected depending on which organ is developing at that time
(Langley-Evans, 2004, Godfrey & Barker 2000, Nyirenda et al., 1998).
Low birth weight is thought to be due to growth retardation due to maternal
undernutrition, which in turn leads to fetal undernutrition (Langley-Evans et al.,
1996a). During the fetal development of protein restricted pregnant rats, it has been
found that brain growth is spared and truncal growth is restricted in the final weeks of
gestation leading to a shorter body, and reduced body weight in the offspring at birth
(Langley-Evans et al., 1996a). The fetus adapts to the undernutrition to allow short-
term survival even though this can lead to irreversible adaptations that can be
detrimental in adult life (Godfrey & Barker, 2000). These adaptations could then
permanently alter the way in which organs develop, therefore programming the
physiology and metabolism of the offspring (Barker & Osmond, 1986).
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1.4 Criticisms of the Fetal Programming Hypothesis
Despite the evidence that supports the fetal programming hypothesis, there have
been robust criticisms of the epidemiological evidence that shaped the concept. In
studies such as the Dutch famine, there is a heavy reliance upon historic records that
may be inaccurate, and may not have recorded the necessary information. This could
be because tracking down individuals for investigation into the onset of adult disease
is difficult, and the study size is not seen as sufficient to gain a thorough conclusion.
Roseboom et al. (2001) stated that birth weight may be a poor indicator for evaluating
nutritional events during pregnancy. Not all offspring have an altered birth weight due
to maternal nutrient restriction, but such restrictions could still have health
implications on the offspring.
One recent study by Langley-Evans & Langley-Evans (2003) in Northampton also
found evidence that conflicted with Barkers low birth weight link to onset of disease
theory. It was suggested that low birth weight, increased placental weight, thinness at
birth and large head circumference of the offspring, predict diseases such as diabetes
and CVD. In this study, maternal nutrient intake in pregnant women during the first
and third trimester was measured to investigate its effects on offsprings birth and
placental weight as well as infant proportions. There was found to be no relationship
between maternal diet in the first and third trimester of gestation and offspring birth
or placental weight. Only thinness at birth was associated with maternal carbohydrate
intake. Mathews et al. (1999) also found no significant relationship between maternal
diet and offspring birth or placental weights.
A study completed by Huxley et al. (2004a) found evidence to suggest that there is no
relationship between birth weight and an offsprings later risk of CVD. It also conflicted
with evidence that individuals born into deprived backgrounds developed hypertension
as adults (Barker & Osmond, 1986). Investigations by Huxley et al. (2004a) were
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completed on the offspring from women who were pregnant during WWII, similar to
that in the Dutch famine study. The pregnant women underwent biochemical tests
completed to analyse markers of nutritional intake and an interview to establish socio-
economic standing. The offspring went through a similar process when located a
number of years later looking for precursors of coronary heart disease. It was found
that there was no link between the offsprings birth weight and the development of
hypertension in later life, and that individuals from higher social backgrounds had
higher blood pressure. This demonstrates the inconsistency in findings across studies,
and that birth weight cannot necessarily be used as a marker of fetal undernutrition.
The programming concept has also been criticised on the basis of inconsistency in
findings and a lack of control for confounding factors in epidemiological studies
(Huxley et al., 2004a). Early studies of associations between birth weight and blood
pressure often overlooked confounding factors, which have the potential to have an
effect on disease onset. The impact of factors such as parental social status and blood
pressure, and offsprings social-economic status, lifestyle in later life were not fully
assessed by the majority of retrospective cohort studies (Huxley, 2004b).
Meta-analyses are being more commonly used in epidemiological investigations,
reviewing data from several studies and providing a more robust and accurate
outcome. Studies by Huxley (2004b) have found that there is variation between
studies of differing subject size. Large studies (3000 subjects) have less significant
data indicating weaker associations between birth weight and blood pressure. Smaller
studies (1000 subjects) on the other hand, appear to have more significant data.
Favour is often given to publication of these smaller studies as they have high impact
findings, so are being more frequently reported. Meta-analysis is a useful tool in the
elimination of this publication bias.
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Huxley (2004b) suggests that human studies finding casual links between birth weight
and disease onset are good for forming hypotheses, but need further investigation
using animal models of programming to support them. Animal studies provide a
means to eliminate discrepancies between studies and investigate the mechanisms of
programming.
1.5 Animal Models of programming
Even though human studies provide the best insight into fetal programming and how
nutritional intake can affect the offsprings risk to diseases, they alone cannot fully
support the hypothesis. It is clear that criticisms of the epidemiological approaches
used have raised significant questions about the validity of assertions made by Barker
and others. Development of animal models of programming has been important in
demonstrating plausibility of fetal programming by maternal nutrition. Animal models
have been developed to explore the theory and back up current findings from human
studies. Such models allow investigation of different dietary intakes in pregnancy
looking, for example, at specific nutrient restriction, which is not feasible in human
studies. These experiments can also begin to explore the underpinning mechanisms
and pathways involved in programming.
Various models of dietary alteration during pregnancy have been established in
animals including rat, pig and sheep with alterations to a normal well balanced diet.
Most experimental diets attempt to demonstrate the biological principles of
programming (Langley-Evans, 2004). Experimental models of diet in pregnancy fall
into a few categories such as variance in total food intake including dietary excess and
restriction, and altering macro- and micro- nutrients such as calcium.
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1.5.1 Restricted Food Intake Models
Global undernutrition is a commonly used approach to investigate the impact of
maternal undernutrition on later CVD risk. This approach is favoured as it produces
fetal growth retardation (Langley-Evans, 2004). Some of the first studies of total
dietary restriction using animal models were completed by Persson & Jansson (1992),
and Woodall (1996). Persson & Jansson developed a guinea pig model to investigate
food restriction in utero. Blood flow was restricted to one horn of the guinea pigs
uterus depriving pups of energy and nutrients, and the other horn had no restriction.
It was found that pups subject to restriction were growth-restricted compared to the
unrestricted pups, and these pups developed higher blood pressure. This
demonstrated that there was a significant association between low birth weight and
elevated blood pressure in later life.
Woodall et al. (1996) investigated restricted food intake in pregnant rats to establish
whether this diet affected blood pressure in offspring later in life. Maternal diet was
restricted by 70% compared to control animals, and it was found that these animals
also had a lower birth weight and developed hypertension. Both of these studies
strongly supported the hypothesis that maternal undernutrition leads to growth
retardation, and predispose offspring to develop cardiovascular abnormalities. In
contrast to other studies, six month old offspring of pregnant sheep fed 50% of the
recommended metabolisable energy intake during days 28-80 of gestation, where
found to develop lower resting blood pressure in comparison to controls, and a low
nephron number (Gopalakrishnan et al., 2005).
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1.5.2 Dietary Excess Models
Increased food consumption above the recommended calorie intake is a driver of
human obesity, and is an ever increasing problem in Europe and the US. In 2006,
approximately 25% of the UKs population were classed as obese (BHF Coronary Heart
Statistics, 2008). Obesity can lead to various life threatening illnesses including type II
diabetes and CHD (Khan et al., 2004). Obesity during pregnancy is also becoming
more common in the UK and US (Akyol et al., 2009), and is associated with
complications such as pre-eclampsia and thrombosis. There is also an increased risk of
delivery complications leading to maternal and infant death (Akyol et al., 2009).
Samuelsson et al. (2008) explored the hypothesis that obese mice during pregnancy
would be more likely to have offspring that developed cardiovascular and metabolic
problems in later life. By feeding mice either a control or highly palatable, high fat
diet, made up of 16% saturated fat and 30% sugar before, during and after
pregnancy, they showed that maternal obesity led to offspring developing
hyperphagia, greater adiposity and hypertension.
The cafeteria diet model is becoming commonly used in the investigation of the impact
of junk food diet on pregnant rats. Akyol et al. (2009) investigated the effects of
feeding twelve high fat food items to rats to induce obesity prior to pregnancy. Pre-
gestational obesity was achieved with this increased calorie diet leading to increased
maternal total body fat. Interestingly, this did not affect reproductive success of the
females, but continuation of feeding throughout pregnancy did lead to reduced weight
in the offspring at gestational age day 20.
Bayol et al. (2008) also investigated the effects of high fat, sugar and salt diet in
pregnant rats. The diet was fed throughout gestation and lactation, and then offspring
were weaned onto standard chow. Adolescent offspring developed increased fat pad
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mass and adipocyte hypertrophy. They also showed raised insulin-like growth factor-1,
insulin receptor substrate- 33$5Ǆ OHSWLQ DQG glucose transporters 1 and 3 mRNA
expression. They are all involved in the regulation of lipid synthesis, adipocyte
differentiation and proliferation, glucose transport and appetite. These increases led to
early onset of hyperglycemia, hyperinsulinaemia and hyperlipidemia.
1.5.3 Nutrient Restriction Models
More commonly used models for the study of fetal programming are ones which
impose a specific nutrient restriction. Not many human populations undergo famine
during pregnancy, rather they lack in specific vitamins, minerals and nutrients.
Several models of nutrient restriction, which assess the impact of such deficits, have
been developed in different animals including rat, mouse, and guinea pig (Langley-
Evans, 2004), which enable studies to examine the effects of relatively small dietary
manipulations.
Iron deficiency is a common problem amongst pregnant women, with up to 30% of
the UK population affected by it. Global prevalence of iron deficiency is estimated at 2-
3 billion, and in developing countries it is seen in 50% of pregnant women (Langley-
Evans, 2009). A model has been developed to investigate how maternal anaemia
throughout gestation affects the health of the offspring. Gambling et al. (2003)
completed a study using dietary iron restriction before and during pregnancy. It was
found that iron intake at 7.5mg/kg diet, compared to control levels at 50mg/kg diet,
significantly increased the offsprings blood pressure, and that hypertension remained
into adult life. These rats were also born with anaemia, even though the diet was
classed as a mild form of iron deficiency.
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Bursey et al., 1983 investigated pregnant rats treated with decreasing concentrations
of dietary sodium throughout gestation, ranging from 0.022% to 0.173%, as a model
of nutrient restriction. It was found that low levels of sodium in the rats diet led to
dramatic effects on the offspring three weeks postpartum. Females fed the lowest two
sodium concentration diets experienced less weight gain during pregnancy, decreased
food consumption, and had smaller litters. Offspring had low birth weight, and
impaired brain development, resulting in smaller brains in comparison to higher
sodium groups. Offspring exposed to the lowest level of sodium did not survive
lactation.
1.5.4 Maternal Low Protein (MLP) Model
Langley & Jackson (1994) developed the low protein rat model that has now become
well established in the investigation of the effects of undernutrition during gestation
upon cardiovascular function. The diet consists of a total protein content of 9% casein
compared to a control diet of 18% casein. This is regarded as a mild form of protein
restriction, and is the concentration required for a non-pregnant rat (Langley Evans,
2004), pregnant rats require 12% protein (Langley-Evans et al., 1994). To match the
control diet total composition, the MLP diet has an increased carbohydrate content
consisting of starch and sucrose (Langley Evans, 2004) and has similar energy
content.
To date, research on MLP fed rats and mice as a model of maternal under nutrition has
provided evidence that this diet leads to offspring developing hypertension (Langley-
Evans et al., 1994, Langley-Evans et al., 1996c, Langley-Evans et al., 1999, Harrison
& Langley-Evans, 2008), abnormal cardiac output (Cheema et al., 2005),
atherosclerosis (Yates et al., 2009) and reduced nephron number (Langley-Evans et
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al., 1999). Maternal protein restriction therefore predisposes the offspring to develop
diseases, including CHD and risk factors for CHD.
MLP diet fed during gestation induces hypertension (blood pressure elevation of 20-
30mmHg) as early as 4 weeks old in offspring, independent of maternal blood
pressure. Hypertension continues throughout life (Langley-Evans et al., 1994). This
increase in offspring blood pressure has recently been identified to pass between
generations (Harrison & Langley-Evans, 2008). Raised blood pressure and reduced
nephron number were identified in the F1 generation, and this was then seen in the
subsequent F2 generation without further dietary manipulation. Decreased nephron
number was passed down both maternal and paternal lines. By the F3 generation
these alterations in blood pressure and renal function were no longer present
(Harrison & Langley-Evans, 2008). Lower nephron number and increased blood
pressure have been suggested to be linked. It has been proposed by Mackenzie et al.
(1995), discussed in Harrison & Langley-Evans (2008), that decreased nephron
number increases blood pressure as a compensatory mechanism, maintaining
glomerular perfusion. The increase in blood pressure then leads to further losses of
nephrons and a vicious cycle begins resulting in hypertension. These transgenerational
effects may be explained by female offsprings cardiovasculature being altered by
maternal diet during their pregnancy. Decreases in vasodilator acetylcholine and beta-
adrenoceptor agonist, isoprenaline, were seen in MLP female offspring towards the end
of pregnancy (Torrens et al., 2003). These are known to contribute to the onset of
hypertension, potentially leading to problems during pregnancy.
As well as the MLP diet causing cardiovascular problems, it also disturbs metabolic and
behaviour of rodent offspring (Bellinger et al., 2005). Environmental factors and
undernutrition in utero can have significant impact on metabolic abilities. Offspring
exposed to MLP in utero, at 18 months old, developed hypertriglyceridemia and insulin
resistance, and a 2-3 fold increase in hepatic triglycerides compared to controls
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(Erhuma et al., 2007). These findings along with a depressed expression of PPARD,
which is involved in lipogenesis and lipid storage, are indicative of metabolic
syndrome.
Bellinger et al. (2005) observed that female offspring fed a MLP diet for one week of
gestation (early, mid and late), consumed less fat when put on a self-selection diet of
high-fat, high-carbohydrate and high-protein in comparison to controls. Conversely,
previous studies have shown that a MLP fed throughout gestation leads to increased
consumption of fat. These changes may be mediated by gonadal steroids as changes
were only seen in female offspring. It was also interesting to note that the MLP diet
had effects before the placenta had been fully established.
Lifespan of MLP offspring, exhibiting low birth weight and increased blood pressure
from an early stage, has been suggested to be reduced by 11% compared to control
animals (Sayer et al., 2001). The rats in this study were left to die of natural causes
assessing only the total lifespan, whereas other studies have investigated the potential
of premature aging (Langley-Evans & Sculley, 2005). At birth MLP offspring displayed
increased oxidation of hepatic proteins, and in later life, at several time points, male
offspring accumulated increased protein carbonyl concentrations in liver, and
increased glutathione peroxidase activity. Increased oxidation promotes apoptosis and
loss of tissue function, so these findings are indicative of premature aging (Langley-
Evans & Sculley, 2005). MLP leads to premature oxidative damage leading to
premature aging and a decreased lifespan.
Protein restriction has also been found to have effects in Apo*E Leiden mice that carry
a mutation making them prone to developing atherosclerotic lesions when fed high
cholesterol diets. MLP diet during gestation combined with atherogenic diet at
weaning, led to the offspring developing a significant increase in the formation of an
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atherosclerotic lesion within the aortic arch, and increased total plasma cholesterol
and dyslipidaemia (Yates et al., 2009).
1.6 The Heart
Within this thesis, study will be focused upon programming effects of MLP diet upon
the heart. It is therefore useful to consider the anatomy, development and function of
this organ.
The heart is a unique organ that every cell in the body is reliant upon. It pumps
approximately 8000 litres of blood a day throughout a persons life span. It pumps
blood carrying oxygen, nutrients, white blood cell and hormones to their intended
destination (Martini et al., 2001b). The mammalian heart is split into four chambers;
two atria and two ventricles. The two ventricles pump blood around the body. The
right pumps to the pulmonary system, oxygenating the blood, and the left pumps 6-7
times more blood to the rest of the systemic circuit. For this reason the left ventricle is
a larger chamber compared to the right, and has a much thicker wall (Martini et al.,
2001b).
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Figure 1.3  Normal and Hypertrophic Heart (Washington University, School of Medicine web
page)
The human heart develops into its complete structure 21 days after conception and
begins to beat (Martini, 2001a), and in the rat it is fully established at 3 weeks
postpartum (Rudolph et al., 1974). During development the rat heart uses different
energy substrates. At birth there is an increased expression of fatty acid transporters,
and glucose transport and oxidation genes are down-regulated (Lavrentyev et al.,
2004). This persists until approximately two weeks postpartum when fatty acids are
no longer the main sources of energy. At three weeks after birth glucose transport and
oxidation genes begin to be up-regulated, and fatty acid uptake is decreased
(Lavrentyev et al., 2004). From this point on, glucose transporters (GLUT) 1 and 4
become the main glucose transporters for the heart.
1.6.1 Cardiomyocytes
The muscle cells of the heart are known as cardiomyocytes, and are responsible for
producing electrical impulses that control the heart. When cells join together they beat
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in unison as excitation spreads from one cell to another (Berne & Levy, 1997). Gap
junctions between cells are connected by either connexins (Berne & Levy, 1997) or
desmosomes (Levick, 2000), which attach the cell cytosol together. Without this
connection ionic currents would not be transmitted from one cell to the next, and so it
ensures the cells of the myocardium work together. If cell linkage is broken, in cases
of tissue damage, oxygen is not effectively delivered to the cells, resulting in impaired
electrical conduction (Levick, 2000).
Cardiac muscle cells fall into two categories, myocytes and the cardiac electrical
system (Levick, 2000). Cardiomyocytes form the majority of the cells of the heart and
carry out the mechanical work (contracting), but can only contract when electrically
stimulated. The electrical supply is provided by a small number of cells that form the
cardiac electrical system, which comprises of sinoatrial node, atrio-ventricular node,
Purkinje fibres, and conduction bundles. These nerve cells manage the heart beat by
initiating and conducting the electrical impulses that stimulate the myocytes (Levick,
2000).
In the rat at birth, cardiomyocytes are approximately 5-6 microns in size, and grow to
15 microns in the adult heart (Rudolph et al., 1974). Human myocytes are
approximately 10-20ǋM in diameter, and 50-100ǋM long (Levick, 2000).
Cardiomyocyte growth occurs in three phases; proliferation, binucleation and
hypertrophy (Ahuja et al., 2007). The two main growth phases in both rats and
humans are termed hyperplastic and hypertrophic. Hyperplasia is where the cells
undergo mitosis and division, increasing the number of cells in the heart tissue (De
Vries et al., 2002). These immature cardiomyocytes are mononucleated, and still have
the ability to divide. Once they are fully differentiated the cells are binucleated, and
are no longer able to divide. They can however undergo hypertrophic growth, where
the cells increase in size and the heart increases in weight (De Vries et al., 2002).
During both human and rodent heart maturation, cardiomyocytes undergo both types
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of growth (Cheema et al., 2005). Hyperplastic growth occurs in the early stages of
development, and hypertrophic occurs in the perinatal stage resulting in a 30-40 fold
increase in individual cell size (Sugden et al., 1999, Oparil, 1984). In the rat,
postnatally cardiomyocytes are predominantly mononucleated as hyperplasia still
occurs in the first few weeks after birth (Cortius et al., 2005), and shortly after, the
cells cease to divide (Oparil, 1984).
1.6.2 Hypertrophy
Whilst hypertrophy is a normal element of the growth of the heart, allowing an
increase in size, adult hypertrophy is also associated with disease. Hypertrophic
growth in adult life is a compensatory mechanism following insult, or when the heart
has to work harder than normal to pump blood, such as during hypertension or
myocardial infarction (Figure 1.3). This growth allows the heart to continue to work at
its normal rate, giving the same cardiac output as before the incident, adapting to its
increased demands (Santalucia et al., 2005, Liao et al., 2002, Sugden et al., 1999).
However, if this type of growth continues, whether it is throughout the heart, or just
ventricular, for a prolonged period, it can have detrimental effects (Santalucia et al.,
2005, Sugden et al., 1999). Hypertrophy can lead to remodelling of the heart,
permanently affecting its ability to dilate and contract (Katz, 2000). There are also
metabolic effects. In the damaged adult heart when hypertrophy has occurred,
glucose oxidation is increased even though heart failure has been linked to a reduction
in glucose transporters (Santalucia et al., 2005). The expression of ventricular GLUT
1, basal glucose uptake is increased, and GLUT 4, insulin regulated uptake is
decreased (Liao et al., 2002, Santalucia et al., 2005).
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The mechanisms and pathways that underlie cardiac hypertrophy are currently poorly
understood. A study completed by Montessuit & Thornburn (1999) investigated the
effects hypertrophic agonists had on rat neonatal ventricular cardiac myocyte cells. It
was found that agonists induced expression of GLUT 1, demonstrating that the heart
requires a high basal energy intake to compensate for work overload. It has been
suggested that cardiomyocyte mitosis (hyperplastic growth) does occur in adult life,
which could provide a means for the recovery of the heart following heart damage
(Anversa et al., 1998).
1.7 Tissue Remodelling as a Mechanism for Fetal Programming
The mechanisms which underpin programming of disease risk are largely unidentified,
but it is likely that changes to physiological function are due to tissue remodelling
(Langley-Evans, 2009). Organ development is complete at birth, with a surge of
cortisol in human tissues that ensure organs are matured in preparation for life. In the
rat, some organ development continues shortly postpartum, for example, the heart
continues to undergo hypertrophic growth for a short period in neonatal life. At this
stage any deficits are irreversible, improper growth of an organ for instance, cannot
be reversed or corrected.
Tissue remodelling is the process where by organs and tissues are permanently
altered in their structure, and hence function. A reduction in cell number or type could
have detrimental effects on an organ, altering the number of functional units leading
to an increased risk of disease (Langley-Evans, 2004). Such alterations have been
frequently found to occur in offspring that have experienced some type of insult in
utero, such as dietary restriction or stress. Feeding rats a low protein diet, for
example, during gestation, impacts on kidney function of the fetus. Mild protein
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restriction mid-gestation increases blood pressure and reduces the number of
nephrons in the kidney (Langley-Evans et al., 1999). It is argued that having fewer
nephrons in the kidney increases local blood pressure in order to maintain renal
perfusions over time, and with further nephron loss, this drives up systemic blood
pressure. Other rodent studies have found that protein restriction during pregnancy
decreases the number of pancreatic E-cells, which permanently changes glucose
homeostasis. This was seen more severely, along with growth defects, in offspring
that were exposed to protein deficiency during both gestation and lactation (Heywood
et al., 2004).
Remodelling has also been identified in the brain tissue in the offspring of rats fed MLP
during pregnancy and lactation (Plagemann et al., 2000). The hypothalamus is
sensitive to hormonal, metabolic and nutritional alterations during development.
Protein deficiency altered the organisation of hypothalamic regulators of body weight
and metabolism leading to low body weight, hypoglycaemia and hypoinsulinemia in
offspring at weaning age. Ventromedial Hypothalamic Nucleus (VNM) and
Paraventricular Hypothalamic Nucleus (PVN), the two main nuclei involved in the
regulation of food intake and weight gain, developed a higher overall mass of neurons,
and the VNM increased in volume. These alterations may be permanent, therefore
offspring of this maternal diet would have permanent disorganisation and dysfunction
of the feeding centres of the hypothalamus (Plagemann et al., 2000). This is of
interest in the context of the altered appetite and feeding behaviours of such animals
(Bellinger et al., 2005)
To date, few studies have investigated remodelling specifically of the heart and
whether permanent alterations to structure predispose offspring of undernourished
mothers to develop cardiovascular abnormalities in adult life. It is well established that
maternal low protein diet during pregnancy induces hypertension in the offspring in
adult life (Langley-Evans, 2004). Cheema et al. (2005) used this rat model to observe
26
if this diet caused structural and functional changes to the heart of the developing
fetus. It was found that the cardiomyocytes underwent hypertrophy, a compensatory
mechanism leading to hypertension, causing left ventricular wall thickening, a known
predisposing factor of heart disease. The reason for the cells undergoing this type of
growth was due to a threefold increase in cell apoptosis, producing a decrease in cell
number, which needed to be replaced by increasing cell size. This in turn also reduced
the ejection fraction (left ventricular end-diastolic volume), which strongly indicates
left ventricular remodelling. Cheema et al. (2005) stated that as aging is a known
driver of such for changes to the heart, that hearts exposed to MLP diet in utero could
be undergoing premature ageing (Cheema et al., 2005).
A maternal low protein diet is also known to cause growth retardation of the
developing fetus, which is thought to be a crude marker for the onset of CVD in later
life (Langley-Evans & Nwagwu, 1998). The reason for this link could be due to a
reduced supply of nutrients affecting cell mitosis in organs and tissues. This growth
retardation affects all organs excluding the brain, and in particular, it is thought that
growth restriction during gestation could lead to a loss of cardiomyocytes of the heart
(Cortius et al., 2005). Cardiomyocytes of low protein offspring underwent normal
hyperplasia during fetal growth, but hypertrophic growth occurred at a much earlier
stage compared to control animals (Cortius et al., 2005). Hearts were found to have a
reduced number of cell nuclei and an overall decreased number of cardiomyocytes, as
well as a significantly reduced cardiac tissue volume and weight. As hyperplasia does
not occur for very long postpartum, these lower numbers of heart cells are likely to
remain throughout adult life (Cortius et al., 2005). As the heart has not developed as
a normal heart would, a period of catch up growth takes place, which is in the form
of hypertrophic growth (Cortius et al., 2005). A premature halt to hyperplastic growth
means that the heart will not have enough functional units in comparison to a control
heart, potentially compromising later function. This is analogous to what is observed
with nephron number in the kidney (Langley-Evans et al., 1999).
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Aroutiounova et al. (2009) supported this finding when investigating the ability of
cardiomyocytes in neonatal rats to replicate. Prior to mating and during pregnancy,
rats were fed either a 9% or 18% casein diet, and following birth they were put on
standard chow throughout the suckling period. The maternal low protein diet
decreased the rate of mitosis in neonates, suggesting that the diet may limit cell
division. This would explain the low number of cells found at birth by Cortius et al.
(2005), as well as the increased apoptosis reported by Cheema et al. (2005). One to
two weeks postpartum, mitosis began to increase in MLP animals, and by one month
there was no difference between controls and low protein animals. This strongly
suggests that chow diet enables the cells to recover and restart replication
(Aroutiounova et al., 2009). This study did not however examine whether the earlier
period of abnormal growth impacted upon function.
Such abnormalities in the heart may predispose offspring of protein restricted mothers
to develop hypertension (Langley-Evans et al., 1995, Langley-Evans et al., 1996a,
Langley-Evans et al., 1999,) and associated cardiovascular disease. These disorders
also cause the heart to respond with another bout of hypertrophic growth (Oparil,
1984). Due to the fact that the heart has already gone through several episodes of
hypertrophic growth in early life in hypertensive animals, the capacity for this type of
growth is much reduced in adult life. This decrease in the hearts capability to increase
tissue mass and poor contractile ability could lead to heart failure. This supports
Cheema et al.s (2005) suggestion that the exposure to MLP in fetal life, leads to the
heart undergoing premature aging. Consistent with this, Elmes et al. (2007) have
found, using the Langendorff perfusion technique, that rats exposed to MLP diet during
development have an impaired recovery of left ventricle pressure following ischemic
reperfusion. This effect was more severe in males than in females. These offspring
also developed hypertension. In addition, the low protein diet altered the hearts
response to E-agonist stimulation in males (Elmes et al., 2009). Stimulation of the
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cardiac E-adrenergic system by E-agonists may contribute to development of heart
failure, as they were found to delay the recovery to basal cardiac function.
Following on from Cheema et al.s (2005) work, where decreased contractile function
was caused by exposure to the MLP diet, the mechanisms of energy utilisation of the
neonatal heart were investigated as a possible reason for apparent remodelling. Using
the same model of maternal protein restriction, the expression of genes regulating
phospholipid metabolism was assessed by Tappia and colleagues (2005). Expression
of MEF-2C (controls glucose supply and utilisation genes) was reduced, whilst PPAR-Į
(involved in the regulation of fatty acid oxidation) was increased. There was also
evidence of increased apoptosis in this study. However, these changes were not to a
level sufficient to alter cardiomyocyte function. This indicates that cell apoptosis is a
more likely cause for a reduced contractile ability (Tappia et al., 2005).
Tappia et al. (2009) investigated if calcium channels were affected by maternal protein
deficiency, as this could play a role in the programming of poor contractile function.
MLP diet was found to affect various components of the regulation of cardiomyocyte
calcium homeostasis. This included reducing mRNA expression of the L-type calcium
channel and increasing Na2+-Ca2+ exchanger expression, as well as depressing
ryanodine receptor protein content and SERCA 2a expression that may be involved in
cardiac contractile mechanisms. However, it was not found that this had a direct
impact on function.
It is becoming clear that, as with other organs, the rat heart undergoes remodelling of
structure in fetuses exposed to maternal protein restriction. It is possible to speculate
on how this may change later function and hence risk of CVD. It is of considerable
interest however, to determine the events that link maternal undernutrition to
permanent changes in organ structure. Although this may simply reflect nutrient
deprivation during phases of growth and maturation, a number of studies have
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suggested that more complex scenarios operate. These include disturbances of the
normal process that regulate the balance of endocrine signals between mother and
fetus.
1.8 Glucocorticoids
Glucocorticoids (GC) are steroids primarily involved in mediating stress-responses, but
are also involved in regulating metabolic and cardiovascular functions. In humans,
cortisol is the main glucocorticoid (Whitworth et al., 2005) and is essential for
maintenance of blood pressure. Natural occurring excess of glucocorticoids results in
Cushings syndrome, when cortisol is over-secreted causing hypertension (Whitworth
et al., 2005). Both systolic and diastolic pressures are elevated and can lead to death
from CVD, and even in treated patients mortality rates are high (Whitworth et al.,
2005). In the rat, corticosterone is the main glucocorticoid. They regulate gene
transcription via the nuclear hormone receptor (glucocorticoid receptor), and
disturbance of the GC axis in the developing fetus may lead to later abnormalities in
glucose metabolism (Nyirenda et al., 1998).
In the case of the developing fetus, GCs are involved in the maturation of organs and
tissues, especially in preparing the lungs for postnatal life (Slotkin et al., 1991, Drake
& Seckl, 2004). Prior to a normal human birth there is a surge of cortisol to the fetus
(Liggins, 1994) to promote the maturation of vital organs such as heart, gut and
kidneys. For this reason, synthetic GCs, such as dexamethasone, are frequently used
in women who are likely to have a preterm delivery. Due to GCs affects on organ
development, they have become extensively used during child birth and in newborns
(Drake & Seckl, 2004). Excess of glucocorticoids during development can however,
have detrimental effects if the fetus is exposed too early. GCs are known to restrict
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growth leading to lower birth weight and alterations in cellular development and
function (Slotkin et al., 1991, Langley-Evans et al., 1997b).
1.8.1 11ǃ-hydroxysteroid dehydrogenase type 2 (11ǃ-HSD-2)
Glucocorticoids during pregnancy can freely cross the placenta, so the fetus needs to
be protected from high concentrations of maternal GCs, so that the fetal
hypothalamic-pituitary-adrenal axis can develop independently (De Vries et al., 2002).
Fetal concentrations of GC are approximately 5-10 times lower in comparison to
maternal levels in humans (Nyirenda et al., 1998) and can be as much as 100-1000
fold in the rat (Drake & Seckl, 2004). The enzyme 11ǃ-hydroxysteroid dehydrogenase
type 2 (11ǃ-HSD-2) acts as the barrier between the mother and fetuss steroids, and
metabolises GCs as they pass across the placenta. In humans, cortisol is converted to
inert cortisone, and in rats corticosterone is converted to 11-dehydrocorticosterone
(Benediktsson et al., 1993). However, this barrier is not always effective and slight
changes in enzyme activity can have significant impacts on the fetus due to the
difference in concentrations of GC. It has been found that if high levels of maternal
steroids reach the fetus, the overexposure can lead to growth retardation of the
offspring (Nyirenda et al., 1998, Langley-Evans, 1997b). This increase can also lead to
premature maturation of organs and tissues (effectively tissue remodelling). Such
alterations can lead to disease onset in later life, thus suggesting that GC
overexposure can have permanent programming effects.
11ǃ-HSD-2 is known to be down-regulated at rat gestational age 20 by MLP diet
(Langley-Evans & Nwagwu, 1998). Langley-Evans et al., (1996c) found that
expression of 11ǃ-HSD-2 was reduced in placentas of pregnant rats fed a low protein
diet, which also led to the offspring developing hypertension in adult life. It was also
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found that if mothers fed this diet were treated with the inhibitor of GC synthesis,
metyrapone, hypertension was prevented from occurring in the offspring (Langley-
Evans et al., 1996, McMullen & Langley-Evans, 2005).
Timing of GC exposure seems to have different impacts on the fetus, for example, rats
treated with dexamethasone specifically in the last week of pregnancy had reduced
birth weight and developed hypertension (Levitt et al., 1996). Inhibition of 11ǃ-HSD-2
using carbenoxolone (CBX), raised blood pressure and decreased birth weight in rat
offspring regardless of timing of treatment. However, greatest increase in blood
pressure was noted when mothers received CBX in the last week of pregnancy
(Langley-Evans, 1997b). It is thought that normal silencing of 11ǃ-HSD-2 occurs at
different times in different organs depending on when maturation is to occur. In mice,
there is a silencing of 11ǃ-HSD-2 around mid-gestation, which could be to allow GC to
have effects in time for birth (Brown et al., 1996).
1.8.2 Dexamethasone
Dexamethasone (Dex) is a synthetic glucocorticoid used as an alternative to the
natural occurring steroid cortisol. It is used in the treatment of preterm births in
humans (Drake & Seckl, 2004), and is commonly used in rodent models of disease.
Dex is a more potent glucocorticoid in comparison to human cortisol and has different
chemical structure (Kamphuis et al., 2007) as illustrated in Figure 1.4 (Cook &
Beanstall, 1987, Wakeling, 1987). It is poorly metabolised by 11ǃ-HSD-2, so easily
crosses the placenta (De Blasio et al., 2007, Dodric et al., 1999, Benediktsson et al.,
1993). This leads to greater active glucocorticoid exposure to the fetus in comparison
to cortisol, of which only approximately 10-20% in humans passes to the fetus (Blasio
et al., 2007).
32
Figure 1.4  Chemical structure of cortisol and dexamethasone (Cook & Beanstall,
1987, Wakeling, 1987)
In comparison to natural occurring glucocorticoids in the rat, Dex has a high binding
affinity to glucocorticoid receptor (GR), but not the mineralocorticoid receptor (MR)
(De Blasio et al., 2007). It has also been noted that it does not completely bind to
these receptors in bovine tissue (Dodric et al., 1999). Studies discussed in Dodric et
al. (1999) have suggested that Dex has a high affinity for the pregnane X receptor
(PXR), which does not bind to natural occurring GCs.
Dex is known to promote differentiation of cells, inhibiting cell mitosis in early
development, as well as inducing growth retardation, alteration of the HPA axis and
increased blood pressure (Dodric et al., 1999). This can have detrimental effects on
the fetal heart as it prevents further growth, resulting in fewer and potentially smaller
cells (De Vries et al., 2002, Slotkin et al., 1991). In rodent models of programming,
Dex has been found to have effects towards the end of gestation, leading to growth
retardation linked to high blood pressure of the offspring in later life (Levitt et al.,
1996). In other studies Dex administered at gestational days 17, 18 and 19 in
pregnant rats led to a reduction in the number of cells in both the heart and kidney
(Slotkin et al., 1991), but it did not affect the overall size of these organs. Low doses
Cortisol Dexamethasone
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of Dex (0.2mg/kg) increased the relative cell size and packing density in the kidney
suggesting an increase in hypertrophic growth.
Dodric et al. (1999) also found that treatment of rats in the last third of pregnancy
with dexamethasone led to increased blood pressure 16 weeks after birth. There
appear to be windows of sensitivity to Dex treatment, which result in different long-
term problems (Dodric et al., 1999). In some cases Dex has been identified to reduce
lifespan (Kamphuis et al., 2007).
Dexamethasone has also been found to alter the expression of the glucose
transporters GLUT 1 and 4, in treated rats. Dex administered mid-gestation induced
growth retardation and hypertension in offspring, which in turn caused up-regulated
GLUT 1 in males (Langdown et al., 2001). It may however not be Dex directly causing
an increase in the glucose transporter, but a response to hypertension.
1.9 Glucocorticoid hypothesis as a Mechanism for Fetal Programming
During development, growth of the fetus is predominantly determined by genetics, but
it is thought that the in utero environment may also have an effect (Langley-Evans &
Nwagwu, 1998). The link between low birth weight and hypertension has been
suggested to be due to fetal overexposure to maternal glucocorticoids, as they are
known to retard fetal growth (Benediktsson et al., 1993, Edwards et al., 2001,
Langley-Evans et al., 1997b, Langley-Evans & Nwagwu, 1998). The hypothesis
proposed suggests that glucocorticoids passing from the maternal system across the
placenta expose the fetus to abnormally high concentrations. This will then lead to
growth restriction and thus alteration in tissue structure and function (Godfrey &
Barker, 2000, Edwards et al., 2001). These permanent changes then predispose the
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offspring to develop cardiovascular, metabolic and behavioural abnormalities (Drake et
al., 2004). The reason for increased GCs passing across the placenta is through
alteration of placental function, (Edwards et al., 2001) caused by a reduction in the
expression and activity of 11ǃ-HSD-2 (Langley-Evans, 1996c, Langley-Evans &
Nwagwu, 1998). The MLP diet has been suggested to cause a decrease in 11ǃ-HSD-2
in the placenta (Langley-Evans, 1996c); the mechanism of this, however, is unknown.
Many animal studies have been completed to investigate this theory, and the most
frequently reported finding from administering GCs during pregnancy is a reduction in
birth weight, suggesting growth retardation of the fetus, and hypertension.
Benediktsson et al. (1993), Langley-Evans (1997a), Langley-Evans & Nwagwu (1998)
all reported that pregnant rats administered glucocorticoids, such as dexamethasone,
led to low birth weight and hypertension in the offspring. Benediktsson et al. (1993)
also reported that rat placental 11ǃ-HSD-2 was positively correlated with offspring
birth weight and negatively with placental birth weight.
Langley-Evans & Nwagwu (1998) investigated the effects of MLP diet fed at specific
time points throughout gestation on placental and fetal growth. The study also
examined markers of glucocorticoid sensitivity including activity of the GC-inducible
enzymes TAT and GPDH. Offspring were born with a low birth weight, and at 4 weeks
postpartum they had developed hypertension. Gestational age 15-22 of MLP animals
appeared to be the most sensitive time of GC exposure, leading to increased brain
GPDH at birth and elevated hepatic TAT in neonates. It is thought that MLP diet led to
prolonged exposure to GCs, which may lead to permanent down-regulation effects of
genes.
Intergenerational effects of glucocorticoid exposure are beginning to be investigated
(Drake et al., 2005). Dex administered during the third week of rat gestation leads to
low birth weight, hypertension and glucose intolerance in the F1 generation. Low birth
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weight was then passed onto F2 males, but this effect was not seen in F3 generations,
similar to that seen in the Harrison & Langley-Evans (2008) study of effects of MLP.
Fetal exposure to GCs early on in development are also thought to affect the function
of the hypothalamic-pituitary-axis (HPA), and this can have profound affects on the
central nervous system and other tissues including the cardiovasculature (Langley-
Evans, 1997b). Langley-Evans et al. (1996b) hypothesised that MLP diet fed to
pregnant rats prior to and during gestation would result in permanent alterations in
the HPA axis. The diet was shown to cause hypertension in the offspring as well as
alterations in HPA-related gene expression. There was an increased activity of
corticosterone-sensitive enzymes related to low hormone concentrations, and
increased GR binding capacity and receptor numbers in the hippocampus of MLP male
offspring. MLP diet decreases 11ǃ-HSD-2, which led to increased sensitivity of the
offspring to circulating glucocorticoids. This was likely to be a life-long effect.
Nyirenda et al. (1998) found giving dexamethasone to pregnant rats in the last week
of pregnancy led to a 10% reduction in birth weight, hyper-insulinaemia and
hyperglycaemia in different forms, as well as an increased expression of hepatic
glucocorticoid receptor. Dex administered at any other time point in pregnancy had no
effect, which demonstrates that GCs have specific effects at different time points of
development.
De Vries et al. (2002) completed a study on newborn rats to investigate how Dex
treatment on days 1, 2 and 3 postnatally, would affect pups one, eight, and forty-five
weeks later. It was found that Dex caused permanent structural differences in the
heart. In treated animals, heart weight was significantly lower, and the protein:DNA
content of the cells was higher in comparison to controls, indicating hypertrophy had
occurred. Increased collagen content of the cardiomyocytes was also found, which
suggested premature degradation. Low DNA content indicated that fewer myocyte
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divisions occurred. From this study it was suggested that hypertrophy occurs in order
for the heart to maintain function, as there is no alternative for the growth of the
heart following GC insult. Glucocorticoids could inhibit mitosis of the cells, preventing
growth of the developing heart, leading to a reduced number of myocytes.
Glucocorticoids effects in utero have been seen in other species as well as that rat. In
the ovine fetal kidney, dexamethasone has been found to programme the renin-
angiotensin system (Moritz et al., 2002). Dex increased AT1 and AT2 receptors in fetal
kidneys, and in this group angiotensin II decreased glomerular filtration rate. Sloboda
et al. (2002) reported that administering betamethasone to pregnant ewes at days
104, 111 and 118 of gestation affected glucose homeostasis of the adult offspring. At
125 days of gestation fetuses exposed to this treatment had increased expression of
hepatic 11ǃ-HSD-1, which is involved in regulation of local tissue levels of GCs. They
also exhibited decreased expression of corticosteroid-binding protein, which regulated
free bioactive GCs, but GR expression was unaffected.
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Figure 1.5 - Flow diagram showing the glucocorticoid hypothesis
1.10 Glucose Transporter Genes
Glucose is the bodys primary energy source and is an essential substrate for the
metabolism of almost all cells. It is transported down a concentration gradient when
energy is needed (Watson et al., 2004). Glucose transporters are the proteins involved
in the uptake of glucose into the cell, enabling cells to function. The two main class I
glucose transporters responsible for the hearts uptake of energy are glucose
Maternal
Undernutrition
Placental 11ǃ-HSD-2 p
n exposure of fetal tissue
to GCs
p proliferation of cells
Early maturation
Disturbed pathways of
gene expression
Permanent
hypersensitivity to
GC
Tissue Remodelling
Adult Disease
38
transporter 1 and 4 (GLUT 1 and 4) (Lavrentyev et al., 2004). These are part of a
large family of 13 genes all involved in glucose uptake in different tissue types (Huang
& Czech, 2007). These transporters are specific transport proteins which facilitate
normal levels of glucose in the body, at around 5-6mM. They control this even when
high levels, or lack of sugar have been consumed, preventing hyper- or hypo-
glycaemia from occurring (Huang & Czech, 2007).
1.10.1 Glucose Transporter 1 (GLUT 1)
GLUT 1 is also known as SLC2A1 (solute carrier family 2, member 1). Its main role in
the heart is to allow cardiac basal transport of glucose across the plasma membrane of
cells. It is predominantly distributed in fetal tissue, and starts to be down-regulated in
early postnatal life (Studelska et al., 1992). In the adult heart however, it still
accounts for approximately 30% of the cardiac uptake of glucose (Laybutt et al.,
1997). During adult life it is highly is expressed in the endothelial cells of barrier
tissues such as the blood-brain barrier (Dobrogowska & Vorbrodt, 1999, Maher et al.,
1994). Expression increases when glucose levels are low in the body therefore
allowing more glucose into the cells, and vice versa, always maintaining a constant
level of uptake (Gould & Holman, 1993).
GLUT 1 is thought to have protective properties in the heart, as demonstrated in a
study completed by Liao et al. (2002). Hypertrophy caused by heart failure was
induced in transgenic mice with over-expression of cardiac GLUT 1. It was found that
these mice had increased survival rates compared to wild type mice, due to the
increase in basal glucose uptake. This suggests that a rise in the expression of GLUT 1
increases the glucose uptake of the cells, enabling the heart to cope with increased
haemodynamic demands.
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1.10.2 Glucose Transporter 4 (GLUT 4)
GLUT 4, also known as SLC2A4 (solute carrier family 2, member 4), is found in various
tissues in the body, including adipose tissue. It can mainly be found in striated muscle
such as the heart. It is thought that it is stored in specialised insulin responsive
intracellular vesicles (Watson et al., 2004), and is redistributed to the plasma
membrane in response to insulin (Huang & Czech, 2007). Insulin stimulation leads to
a 20-fold increase in GLUT 4 in the plasma membrane (Watson et al., 2004). Glucose
transport into the cell depends mainly on the number of GLUT 4 receptors on the
membrane. Therefore, if there is a surge in glucose concentrations, insulin will be
activated, which in turn activates GLUT 4 expression on the plasma membrane,
increasing glucose uptake in the cell. GLUT 4 works by trafficking glucose into the
muscle where it is stored as glycogen and then metabolised. This mechanism of
glucose removal controls the levels of glucose in the cells allowing normal function,
maintaining homeostasis (Huang & Czech, 2007). This transporter has low expression
during fetal development, and begins to be up-regulated in early postnatal life to
become the main glucose transporter in the heart (Studelska et al., 1992),
maintaining glucose balance in cells. Due to this, glucose uptake becomes more
susceptible to changes in response to insulin concentrations.
Various studies have been completed to assess the outcomes of altered GLUT 4
regulation. Commonly, studies use a model of GLUT 4 over-expression, or knockout
mice for the investigation of GLUT 4s effects on glucose metabolism in skeletal
muscle, obesity, and type II diabetes (Tsao et al., 2001, Zisman et al., 2000). GLUT 4
deficiencies can lead to growth retardation, decreased sensitivity to insulin
stimulation, and cardiac hypertrophy in mice (Katz et al., 1995). GLUT 4 knockout
mice also exhibited an increased in glucose transporter 1, thought to be a possible
compensatory mechanism to maintain a normal glucose levels. They developed
hyperinsulinaemia following food intake. Cardiac hypertrophy was noted in early life
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and led to increased mortality (Katz et al., 1995) demonstrating that GLUT 4 is vital
for normal physiological homeostasis.
1.10.3 Glucocorticoid Receptor (GR)
The Glucocorticoid Receptor is a member of the nuclear receptor subfamily 3, group C,
member 1 (NR3C1) of ligand-activated transcription factors (Seckl et al., 2004). It is
expressed in most fetal tissues from an early stage and is highly expressed in the
placenta (Seckl et al., 2004), as well as in every cell in the adult body. Its main role is
acting as the receptor that glucocorticoids, including Dex and cortisol, bind to. It is
thought that these receptors are involved in the majority of glucocorticoid effects on
the body (Cole et al., 1995), although GC can also bind to the mineralocorticoid
receptor (MR), particularly in late gestational stages in the rat (Seckl et al., 2004).
The level of expression is different in every tissue, and in some cases expression
varies regionally within specific tissues (Herman et al., 1989).
Since glucocorticoids have a very important role in the body, especially during fetal
development, alterations in GR expression can have a significant impact on
development, growth and metabolism. GRs are expressed in most fetal tissue (Drake
& Seckl, 2004), and in mice it has been found to expressed from approximately day 9
of gestation (Cole et al., 1995). Reduction in GR can lead to abnormalities in adult
blood pressure (Lillycrop et al., 2005), and there is evidence to suggest that events
during fetal growth can programme GR gene transcription in certain tissues or organs
(McCormick et al., 2000). Lillycrop et al. (2005) found that MLP diet fed during
gestation has implications for GR expression in the offspring. MLP diet increased GR
methylation status in the offsprings liver at weaning. These changes are known to
remain into adult life thus affecting blood pressure regulation and risk of developing
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CVD (Lillycrop et al., 2005). Expression of GR during fetal development is however,
still poorly understood.
1.11 Cell culture vs animal studies
Animal models as described in this thesis have been crucial in the advancement of
understanding of fetal programming, and have been the basis of a vast array of
research. Such advancements in scientific understanding could not have taken place
without these animal models. There is, however a need to reduce animal work as a
main experimental model. Ethically the use of animals in science is questionable and
current emphasis is on replacement, refinement and reduction.
There are various advantages and disadvantages in using cell culture as an alternative
experimental model. Using primary culture and cell lines has the potential to reduce
the number of animals currently used in scientific trials, as well as reducing cost.
Scientists are always exploring new methods to move away from animal work, or at
least ways to reduce the numbers used and reduce animal suffering. Cell culture
would eliminate housekeeping and husbandry costs associated with animal care, and
possibly result in quicker trials.
Using culture could also increase the number of endpoint measurements. For example,
in the study described in this thesis, one litter of neonatal rat hearts produced millions
of cells enabling numerous experiments and measurements to be completed, as well
as many replicates. Cells can be manipulated in ways that animals cannot due to
ethical restrictions. For example, cells cultured in plates can be treated with toxic
levels of drugs, or hormones to monitor responses, or even add several treatments
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simultaneously to one culture. It is desirable to develop culture models to become as
standard as animal models, such as the MLP rat model of programmed CVD.
However, there are restrictions associated with using culture instead of animals. The
main problem is that culture does not allow experiments to investigate how body
systems and organs interact, or how each system impacts on the other. Also, some
animal models currently used would take a considerable amount of time to establish in
culture. This is an area that still requires work to develop cell culture into a feasible
alternative to animal trials. For the time being cell culture will be used alongside
animal trials with the aim to reduce the numbers used in the future.
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1.12 Aims
This study has been designed to investigate the impact that fetal exposure to a
maternal low protein diet has on primary cultures of neonatal cardiomyocytes. Animal
trials and primary cell culture work will be completed to explore glucose uptake of
cardiomyocytes, and expression of genes involved in glucose metabolism, exploring
the contribution of glucocorticoids.
The primary aim of this project is to show if programming can be demonstrated in cell
culture. Do neonatal cardiomyocytes insulted with low protein and control diet during
pregnancy hold a memory of maternal diet? The project will investigate if effects of
maternal diet on the heart, such as a reduced nuclear number get passed on through
cell division onto daughter cells. Secondly, the project is designed to investigate
whether synthetic glucocorticoids affect the responses of the cultures. Are proliferation
rates, glucose uptake, and gene expression affected by addition of dexamethasone
into culture? Addressing these questions may begin to explain the mechanisms that
are involved in fetal programming leading to cardiovascular disease.
At this present time there is major interest in the potential contribution of epigenetic
markers to developmental programming. Undernutrition appears to reset such
markers, producing permanent changes in gene expression (Lillycrop et al., 2005). GC
exposure also appears to have the potential to act in this manner. The
transgenerational effects of MLP and Dex reported previously (Drake & Seckl, 2004,
Harrison & Langley-Evans, 2008) seem consistent with an epigenetic mechanism. The
finding of programmed effects upon cultured cells would add further support to this
concept.
44
1.13 Hypotheses
The studies described in this thesis have been performed to test the following
hypotheses.
1. Primary cultures of neonatal cardiomyocytes will retain a cellular memory of
maternal diet, and manifest differences in metabolic function, rates of
proliferation and apoptosis that are associated with maternal protein
restriction.
2. Maternal undernutrition will programme expression of genes involved in
glucose uptake.
3. Maternal protein restriction will increase sensitivity to synthetic glucocorticoids
in cultured cardiomyocytes.
4. Expression of glucocorticoid receptor in cultured cells will be programmed by
maternal protein restriction.
These studies will enable development of new approaches to the study of fetal
programming, and add to understanding of how the diet contributes to tissue
remodelling and sensitivity to glucocorticoid signal in early life. Various lines of
investigation will be undertaken to test these hypotheses. Proliferation, differentiation
and cell apoptosis of the cardiomyocytes will be measured by determination of protein
and DNA content and binucleation in cultures. Functional responses of the
cardiomyocytes to synthetic glucocorticoids will be measured by assessing glucose
uptake. Gene expression will be assessed by measuring glucose transporter 1 and 4
and glucocorticoid receptor mRNA expression in cultures.
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2 Chapter 2
Materials and Methods
All experimental procedures described were conducted under license and in
accordance with the Home Office Animals (Scientific Procedures) Act 1986.
2.1 Animals
Experimental animals were Wistar strain rats supplied by Harlan Laboratories
(Bicester, Oxon, UK). All animals were housed in wire mesh and Perspex cages, in
groups of two per cage, in a controlled environment (21ºC, 55% humidity, 12:12 hour
light: dark cycle) until the start of trial. Prior to mating stud males and females were
fed ad libitum standard, non-purified, laboratory chow diet (Harlan, UK) and had free
access to water.
2.1.1 Maternal Protocol
Individual virgin females, weighing between 210-260g were caged in wire bottomed
mating cages with a stock stud male. Mating was confirmed by appearance of a semen
plug on the cage floor and this day was denoted Day 0 of pregnancy. Pregnant
females were then individually housed throughout gestation and fed an experimental
diet of either control (18% casein) or low protein (9% casein), and water ad libitum.
See Table 2.1 for the composition of diets (Langley-Evans et al., 1994).
To prepare diet, dry ingredients were weighed out and mixed thoroughly before
adding the corn oil. Once this was mixed in, water was added until the mixture
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became dough-like. Balls of diet were baked in an oven at 60ºC for 48 hours, and then
frozen at -20ºC prior to use.
Table 2.1 - Composition of Diets
Ingredient Control Diet - 18%
Casein (grams/kg)
Low Protein Diet - 9%
Casein (grams/kg)
Casein 180 90
Cornstarch 425 485
SolkaFlok (Cellulose) 50 50
Sucrose 213 243
Choline Chloride 2 2
DL-Methionine 5 5
AIN-Minerals 20 20
AIN-Vitamins 5 5
Corn Oil 100 100
2.1.2 Neonatal Protocol
After parturition, the females were culled using a Schedule 1 method (CO2 asphyxia
and cervical dislocation). Eight neonates from each litter (where possible 4 female and
4 male) were also culled using Schedule 1 techniques (cervical dislocation). Each
whole pup was placed in a Falcon tube containing 30ml of ice cold calcium and
magnesium free Hanks Balanced Salt Solution (CM-HBSS) (Worthington Neonatal
Cardiomyocyte Isolation System kit, Lorne Laboratories, UK). Neonatal hearts were
dissected out under sterile conditions to reduce the risk of infection of subsequent cell
cultures.
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2.1.3 Cell Culture Protocol
Cardiomyocytes were seeded onto 24 well plates and grown in a DMEM solution (See
Appendix) for ten days. On Day 11 (baseline time point) one set of cells were lysed
from the plates and stored at -80ºC until analysis. The remaining cells underwent
dexamethasone (Sigma, UK) treatment and were incubated until Day 13 of culture (48
hours time point/Day 2) before analysis.
For trial one, cells were treated with 0, 100nM or 10µM dexamethasone. 100nM was
within the physiological glucocorticoid range (Flagel et al., 2002), and 10µM was
added to consider the maximal cardiomyocyte response. For trial two, cells were
treated with 0, 10nM and 100nM, which were entirely within the physiological range.
2.2 Cell Culture
2.2.1 Isolation of Neonatal Cardiomyocytes
This method was adapted from the commercially available Worthington Neonatal
Cardiomyocyte Isolation System kit (Lorne Laboratories, UK). Each kit can culture 5-
15 hearts per preparation using hearts taken from 1-7 day old rat pups, requiring two
days to prepare under sterile conditions, in a cell culture laminar flow hood. All
reagents were provided in the kit and were prepared before starting the protocol, see
Appendix.
Neonatal pups were culled and dissected as described in Section 2.1.2. The heart of
each pup was placed in a sterile Falcon tube containing 20-30ml of CM-HBSS. Once all
hearts were dissected, the tube was swirled to clean the hearts and CM-HBSS was
removed and discarded. A further 10ml wash of CM-HBSS was added and then
removed. The hearts were then placed in a petri dish and using a sterile disposable
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scalpel knife cut into approximately 1mm3 pieces. 9ml of CM-HBSS was added to the
petri dish, followed by 1ml of trypsin reagent, which was mixed by swirling the dish
(final trypsin concentration was 50µg/ml). The petri dish was taped closed and placed
in a fridge (2-8°C) overnight for 16-20 hours.
After this time the petri dish was removed from the fridge and kept on ice. The
contents were transferred into a sterile 50ml Falcon tube and 1ml of Trypsin Inhibitor
reagent was added and mixed. This was incubated in a water bath at approximately
30-37°C for 40 minutes. Following this, 5ml of collagenase reagent was added and
incubated at 30-37°C, in a water bath set to shake at 2-4rpm, for a further 40
minutes. Trypsin and collagenase are enzymes that breakdown the extra-cellular
matrix of heart tissue.
The solution was then triturated gently 10 times using a serological pipette and cells
were left to settle. A fresh 50ml Falcon tube was set up with a cell strainer, and 1ml of
filtered L-15 medium was passed through followed by the cell supernatant, leaving a
clump of tissue at the base of the first Falcon tube. A further 5ml of L-15 medium was
added to this, and again triturated gently 10 times, allowing the cells to settle after.
The supernatant was again transferred through the cell strainer and a further 2ml of
L15 medium was passed through. The cells were left to stand for 20-60 minutes at
room temperature.
After this time they were centrifuged at 94g, for 5 minutes, at 20ºC. The supernatant
was then removed leaving the pellet at the base of the tube. 5ml of Advanced
Dulbecco's modified Eagle medium/F12 solution (DMEM) (Invitrogen/Fisher Scientific,
UK), fetal bovine serum (FBS) (Heat inactivated Sigma, UK), penicillin-streptomycin
(P/S) (Sigma, UK) and Fungi-zone (GIBCO/Fisher Scientific, UK) solution was added
and thoroughly mixed (See Appendix for details of DMEM solution). 100µl of the cell
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suspension was taken to complete a cell count and the cells were diluted accordingly
with DMEM solution to seed cells at approximately 100,000 cells/ml/well.
24-well plates (Falcon, UK, Polystyrene, non-pyrogenic, TC treated by vacuum gas
plasma) were seeded at 100,000 cells/ml/well and left at 37°C (5% CO2) for 24 hours
before changing the medium. DMEM solution was then changed every 48 hours after
this for 9 days.
2.2.2 Detaching cells from plates to perform a cell count
This method was taken from the Sigma cell culture manual 2008-2009, 3rd Edition. It
was partly completed under sterile conditions, see Appendix for reagents.
DMEM solution was removed from each well and washed using sterile PBS. 0.5ml of
trypsin (Fisher Scientific, UK) was added, and wells were incubated for 3-4 minutes at
37oC. The plate was tapped on the side and viewed under the microscope to check
that the cells had detached. Cells were re-suspended in 1ml/well of DMEM, transferred
to an eppendorf tube, and centrifuged at 10,000rpm for 5 minutes at 18oC. The
supernatant was removed and replaced with 1ml of DMEM and mixed thoroughly.
Approximately 20-40µl was taken to complete the cell count detailed in Section 2.2.3.
Counts were completed before the cardiomyocytes were plated, and after 10 and 12
days in culture (baseline and 48 hour time points).
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2.2.3 Cell Count/Haemocytometer Protocol
Some of the cell suspension (20µl) was taken and gently pipetted into the groove
between the haemocytometer and the cover slip. The cell suspension was drawn under
the cover slip by capillary action. The haemocytometer was secured on the microscope
and the 40x objective used. Cells were counted in either ten of the 1/16mm2 squares
in the top and bottom grids, or eight 1mm squares on two grids as shown in Figure
2.1, depending on the concentration of the cell suspension. To calculate the total
number of cells, the following calculations were completed:
Ten of the 1/16mm2 squares
Total number of cells per ml = Average number of cells in two grids x (1.6x105)
Eight 1mm squares
Total number of cells per ml = Average number of cells in two grids x (1x104)
Figure 2.1  Haemocytometer Grid
1mm
1/16 sq. mm
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2.2.4 Trypan Blue Cell Counting
This method was adapted from Sigma cell culture manual 2008-2009, 3rd Edition, and
was used to identify dead and live cells. Trypan blue is taken up by the dead cells so
they appear blue, and live cells are clear. Before completing the cell counting as
detailed above, 20µl of cell suspension was taken and mixed in a separate eppendorf
tube with 20µl of trypan blue (Sigma, UK). 20µl of this mixture was taken and counted
using the haemocytometer method. Counts were multiplied by 2 to account for the
dilution factor.
2.2.5 Cardiomyocyte Staining
In order to assess the stage of cell differentiation, cultures were stained with a nuclear
stain. DMEM solution was carefully removed from each well and 300µl of 1mg/ml
bisbenzamide (Sigma, UK) solution was pipetted down the side of the well. This was
removed after 4 minutes. Cells were washed with 1ml of 1x PBS solution and imaged
using Leica Application Suite (Leica Microsystems Ltd). Binucleated, mononucleated
and the total number of cardiomyocytes were counted in five microscope fields per
well. All staining was completed in duplicate. In order to determine how many images
were needed for accurate counts, 10 images per well were counted in comparison to
five, which generated the same answer. It was therefore determined that counting five
images per well was representative of the entire well.
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Figure 2.2  Bisbenzamide (1mg/ml) stained cardiomyocytes at a 20x0.3
magnification
Control Culture - 0 Dex
MLP Culture  100nM Dex
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2.3 Chemical Analysis
2.3.1 Cell Lysis for DNA and Bradford Assay
The cell lysis method was taken from Molecular Cloning, A Laboratory Manual, 2nd
edition (1989), and the lysis buffer was taken from Cell Biology Catalogue, Millipore,
2007.
DMEM solution was removed from each well and 300µl cell lysis buffer (see Appendix
for details) was added and incubated on ice for approximately 20 minutes. Cells were
detached from the wells using a cell scraper, and then harvested into a chilled
microcentrifuge tube and centrifuged for 2 minutes, at 12,000rpm, 4qC. The
supernatant was transferred to a fresh microcentrifuge tube, and frozen at -80ºC until
analysed.
2.3.2 Determination of Protein - Bradford Assay
Protein was assayed using the Bradford 1976 method. Reagents are described in
Appendix. Prior to analysis cell lysates were thoroughly defrosted. 10µl of each
sample, standard, blank and QC was added in duplicate to a 96-well, flat bottomed
microplate (Sarstedt) and mixed with 200µl of the Bradford reagent. Protein
concentration was determined from a standard curve prepared in duplicate from
dilutions of 1mg/ml BSA (Sigma, UK) dissolved in water at 0-8µg/ml. The plate was
left for 10 minutes and the absorbance was measured at 560nm using a microplate
reader (Tecan Sunrise, UK) interfaced to the Magellan Version 4.0 computer package.
Trial one inter-assay variation was 2.59%, and intra-assay variation was 0.63%. Trial
two inter-assay variation was 1.01%, and intra-assay variation was 0.72%.
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2.3.3 Determination of DNA Content  Hoechst Fluorometric Method
This method was adapted from Daxhelet et al. (1989). Reagents were prepared as
detailed in Appendix. Cell lysates were thoroughly thawed before analysis. 100ǋl of
each sample, standard, blank and QC was added in duplicate to a black 96-well
microplate (Costar, UK) along with standards made from a stock calf thymus DNA
solution (Sigma, UK) of 1mg/ml. A top standard of 40ǋg/ml was prepared and from
this, serial dilutions were prepared ranging from 0.312 to 20ǋg/ml. Bisbenzamide
(Sigma, UK) dye solution was added to each well at 100ǋl, and then scanned
immediately on the fluorescent plate reader (FLUROstar Optima, BMG Labtech, UK),
with an excitation wavelength of 355nm and emission wavelength of 544nm. Trial one
inter-assay variation was 7.19%, and intra-assay variation was 3.79%. Trial two inter-
assay variation was 4.95%, and intra-assay variation was 2.56%.
2.3.4 Determination of Cell Death
This method was adapted from the commercial Roche Cell Death ELISAPLUS kit. All
solutions were provided in the kit and prepared according to the manufacturers
instruction (see Appendix). Cell culture plates were spun at 2000rpm for 10 minutes at
room temperature before carefully removing the medium and discarding. Plates were
then immediately frozen at -80°C until ready for analysis.
Plates were then thawed for 30 minutes before adding 200µl of lysis buffer, which was
then incubated for a further 30 minutes at 15°C to 25°C. The whole plate was
centrifuged at approximately 2000rpm for 10 minutes at room temperature, and the
supernatant removed. To a 96-well Streptavidin coated plate, 20µl of each sample was
carefully added in duplicate, along with a positive control, background control and QC.
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80µl of the immunoreagent was added to each well. The plate was covered and
incubated on a plate shaker at 300rpm, for 2 hours, at a temperature of 15°C to 25°C.
The solution was then thoroughly removed and each well was rinsed 3 times with 250-
300µl of incubation buffer. 100µl ABTS solution was added to each well and incubated
on a plate shaker at 250rpm for 10 minutes. This was adequate time for the colour to
develop sufficiently for photometric analysis. 100µl of ABTS Stop Solution was added,
and at this stage 100µl of ABTS Stop Solution was added to 2 separate wells to use as
a blank. The plate was read immediately on a fluorescent plate reader (Tecan Sunrise,
UK), using a wavelength of 405nm with a reference wavelength of approximately
490nm. Sample data was calculated as a ratio against the quality control. The inter-
assay variation for this assay was 3%, and the intra-assay variation was 2%.
2.3.5 Glucose Uptake Assay
Basal and insulin-stimulated glucose uptake was determined using a radioisotope-
based method adapted from Kozma et al. (1993). Basal cultures were not treated
before glucose uptake was measured, and insulin-stimulated cells were incubated in
insulin for 30 minutes before glucose uptake was measured. Reagents were prepared
as detailed in Appendix. Cells were removed from the incubator and carefully washed
twice in 1ml of warm (37°C) PBS. For baseline plates, 1ml of PBS containing 200nM of
insulin (from bovine pancreas, Sigma, UK) was added to two of the wells, and to
another two wells 1ml 1x PBS was added. For 48 hour plates, 1ml of PBS per well
containing 200nM of insulin was added to six of the wells, and to another six wells 1ml
1x PBS was added as shown in Figure 2.3. To two separate wells containing no cells,
1x PBS was added. These wells were used as blanks. The cells were then incubated for
30 minutes at 37°C and again washed twice with 1ml of warm PBS.
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After washing, 1ml of warm PBS containing 0.1mM 2-deoxyglucose (2-dG) (Sigma,
UK) and 1ǋCi 2-deoxy-D-[2,6-3H]glucose (3H-2-DG) (GE Healthcare Ltd, UK) was
added to all wells for 5 minutes at room temperature. The assay was terminated
rapidly by washing each well 3 times with 1ml of ice cold PBS. Cells were left to lyse
for 1 hour, at room temperature, in 0.4ml of 1% SDS. Each well was then scraped
with the pipette tip and the contents were transferred into a scintillation vial insert,
and 4ml of Emulsifier Scintillator Plus (Perkin and Elmer, UK) was added and mixed
thoroughly. Inserts were placed in a vial and counted immediately on a liquid
scintillation analyser (TRI-CARB 2100 TR).
Calculation of Uptake
dpm x 12 = pmoles/hour
10.12 x 103
pmoles/hour x 106 = pmoles/hour/million cells
Cell Count
Figure 2.3  24 well, Day 2 cell culture plate setup
No Dex
10nM Dex
1µM Dex
Insulin Stimulated
UptakeBasal Uptake
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2.4 Real-time PCR
2.4.1 Cell Preparation for RNA extraction
For this section of the trial, cardiomyocytes were seeded at 200,000 cells/well in 12
well plates to ensure there were enough cells to achieve adequate amounts of RNA,
for cDNA synthesis. Cultures were grown exactly the same as 24 well plates and
treated with 2ml of dexamethasone in DMEM to cover the larger well size. DMEM was
removed, and each cell culture well was carefully washed with 1ml of sterile PBS
(Sigma, UK). This was removed and 200µl of PBS was then added. The well was
scraped using a cell scraper, and then with a P1000 pipette tip before cells were
placed in a sterile eppendorf tube and snap frozen in liquid nitrogen and stored at -
80ºC. For each day and treatment group, three wells of cells were prepared.
2.4.2 RNA Extraction and DNase Treatment
This method was modified from the commercial Qiagen RNeasy Mini kit. All solutions
were provided in the kit and prepared according to the manufacturers instruction, see
Appendix.
The cells were defrosted and all three wells were mixed to make one cell suspension
for each time point and treatment group. To each sample, 800µl of RLT buffer plus E-
mercaptoethanol (E-ME) solution was added and mixed well by pipetting several times.
Then, 1400µl of 70% ethanol was added and, again, mixed thoroughly by pipetting.
700µl of this solution was passed through an RNeasy spin column placed in a 2ml
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collection tube, and spun for 15 seconds at 10,000rpm. This was repeated until all of
the cell suspension solution was used, discarding the flow through after each spin.
At this stage the samples were DNase treated to remove any DNA contamination. To
each sample, 350µl of Buffer RW1 was added and centrifuged for 15 seconds at
10,000rpm to wash the spin column membrane, discarding the flow through. 80µl of
the incubation mix was then added, ensuring it was added directly to the membrane.
This was left for 15 minutes at room temperature. Following this, another 350µl of
Buffer RW1 was added to the spin column, and centrifuged for 15 seconds at
10,000rpm, again, discarding flow through.
Another wash step was completed using 500µl buffer RPE and centrifuging for 15
seconds at 10,000rpm, the flow through was discarded. A second aliquot of 500µl
buffer RPE was washed through by centrifuging for 2 minutes at 10,000rpm. This step
ensured that no ethanol was carried over during RNA elution, as residual ethanol may
interfere with downstream reactions.
Using a fresh collection tube, the column was spun for another 1 minute at 10,000rpm
to eliminate any possible carryover of Buffer RPE, and prevent any residual flow-
through remains on the outside of the spin column. The column was then transferred
to a sterile eppendorf tube, and 30µl of RNase free water was added directly to the
membrane, and centrifuged for 1 minute at 10,000rpm to elute the RNA. This was
then frozen at -80ºC until ready for cDNA synthesis.
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2.4.3 RNA Quantity and Quality
RNA quantity was measured using a Nanodrop ND1000 spectrophotometer (Thermo
Scientific, UK), which measures the sample by creating a column of liquid and passing
light through it, producing a concentration expressed as ng/µl.
Samples stored at -80ºC were placed immediately on ice to defrost. They were mixed
thoroughly using a pipette, and 1.5µl of each sample was loaded onto the nanodrop
for analysis, in duplicate. The RNA quality was determined from the 260nm:280nm
ratio, which should fall between 1.8 to 2.0.
Before synthesising cDNA from the RNA, samples were standardised to 20ng/µl by
diluting with RNase free water. Samples that were below 20ng/µl were added in a
higher volume to make up to this concentration. Once all were standardised, samples
were examined to ensure they were not contaminated and only produced one product.
As the RNA concentration was too low to run on an Agarose gel, RNA samples were
run on a Roche 480 lightcycler with the E-actin housekeeper gene, and each of the
samples cDNA to check this. RNA samples should appear negative, meaning they are
not contaminated with DNA, and cDNA should have one product. See section 2.4.6 for
the RT-PCR step. Samples were then stored at -80ºC until required for analysis.
2.4.4 cDNA synthesis/Reverse Transcriptase
RNA is converted to cDNA by reverse transcription. Complementary base pairing of the
RNA strand forms the double stranded cDNA molecule. Due to some RNA samples
having a higher concentration than 20ng/µl and some lower, different volumes of RNA
and primers were added at this stage. For samples with initial RNA concentration of
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20ng/µl, 10µl of diluted RNA was added along with 1µl of random primers, and 4µl of
water, to each reaction tube. For samples with initial RNA concentration of <20ng/µl,
1µl random primers was added along with a specific volume of neat RNA to make up
to the required concentration of 20ng/µl. For samples to be used in the standard curve
pool and non-template control (NTC), 5µl of neat RNA or water was added, with 1µl of
random primers and 9µl of water.
Samples were loaded into a 96 tube plate along with primers and water, as detailed
above, and then loaded onto the PCR machine (Gene Amp PCR System 9700, Applied
Biosystems) to incubate for 5 minutes at 70ºC to denature the structure, and then
immediately put on ice. To each tube the following was then added: 5µl MMLV reverse
transcriptase buffer x5 (Promega, UK), 1.25µl of nucleotides (10mM each) (Promega,
UK), 0.5µl of RNase inhibitor (Promega, UK), 1µl of MMLV reverse transcriptase
(Promega, UK), 2.25µl of RNase free water. A master mix of these reagents was made
up prior to use and 10µl of this was added to each sample.
The samples were then incubated at room temperature for 10 minutes, centrifuged for
approximately 5 minutes at 1000rpm. They were then returned to the PCR machine to
incubate at 42ºC for 60mins to transcribe the complementary strand to the RNA, and
then held at 4ºC. All samples and the NTC had 75µl of RNase free water added, except
for the standards. These were then frozen at 20ºC until ready for further analysis.
2.4.5 Standards
Five of the highest concentrated RNA samples had cDNA synthesised separately using
neat RNA to achieve a concentrated cDNA pool. These five samples were pooled and
added to 25µl of water. This pool was then serially diluted using RNase free water
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(Sigma, UK) ranging between 0.016-0.5 to produce a standard curve. This was run on
every plate with each gene of interest.
2.4.6 Real time PCR
Real time PCR is the process where cDNA is exponentially amplified using primers,
which are complementary to a defined sequence on the DNA strands. In this thesis,
SYBR green was used as the dye that binds to the double stranded product and
fluoresces. As illustrated in the diagram below (Figure 2.4), cDNA is heated to high
temperatures of 95ºC to denature the DNA separating the two strands. It is then
cooled to 60ºC allowing the primers to anneal to the complementary site on the
strands. By increasing the temperature to 72ºC enables the enzymes to extend the
DNA strand from the primer region. SYBR green binds to the amplified DNA and the
fluorescence increases as the DNA amplification is increased, and this degree of
amplification is quantified.
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Figure 2.4  Three main steps of polymerase chain reaction (PCR)
Double stranded DNA is denatured, primers then anneal to complementary site on the DNA strands and they
are then extended using enzymes. SYBR green (shown by the green dots) binds to double stranded DNA
and fluoresces.
http://images.the-scientist.com/supplementary/html/36978/sybr.jpg
Primers were diluted with RNase free water (Sigma, UK) according to the
manufacturers instructions. From this a 1:10 dilution was made of each primer
(forward and reverse) in a sterile eppendorf, which were used to make the master mix
for each gene.
The master mix was prepared on ice before loading the 384 well plate, using SYBR
green (Roche, UK) as the dye, which binds to any double stranded product. Each
master mix contained: 7.5µl SYBR master mix, 0.45µl forward primer (10µM), 0.45µl
reverse primer (10µM) and 1.6µl molecular grade water, which was made up for all
reactions. cDNA was fully defrosted and 5µl of each sample, standard, and blank (no
template control) was added along with 10µl of master mix. Each reaction was
completed in triplicate, and this was repeated for all genes.
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Once the plate was set up, it was sealed with an adhesive cover, mixed and
centrifuged for approximately 3 minutes at 1000rpm. The plate was then run on the
Roche Light Cycler-480 machine for 45 amplification cycles. Pre-incubation at 95ºC for
5 minutes is completed to activate enzymes in the master mix, and then 45 cycles
consisting of 95ºC for 10 seconds, 60ºC for 15 seconds and 72ºC for 15 seconds.
Crossing points were calculated using the Lightcycler 480 software, version 1.5.
Samples were measured off the standard curve and gene expression normalised to
Cyclophilin A, which was used as the housekeeper gene.
2.4.7 Design of primers for Rat Genes
Primer sets were required for rat E-Actin, Cyclophilin A, Glucose transporter 1 (GLUT
1), Glucose transporter 4 (GLUT 4), and Glucocorticoid Receptor (GR). Primers were
designed using Primer 3 (Biology Workbench), as well as Primer Express (Table 2.2).
Ensembl was used to find the genomic sequences and was also used to blast the
designed primers. The sequences were found under the following accession numbers;
E-Actin, NM_031144, Cyclophilin A, NM_017101, GLUT 1, NM_138827.1, GLUT 4,
NM_012751.1 and GR, NM_012576.2.
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Table 2.2  Primer sets used for measurements of gene expression
Gene Forward Primer Reverse Primer
E-Actin TCAGGTCATCACTATCGGCA
Tm=57.3ºC GC Content=50%
Length=20bp
CGGATGTCAACGTCACACTT
Tm=57.3ºC GC Content=50%
Length=20bp
Cyclophilin A TGATGGCGAGCCCTTGG
Tm=57.6ºC GC Content=64.7%
Length=17bp
TCTGCTGTCTTTGGAACTTTGTC
Tm=58.9ºC GC Content=43.5%
Length=23bp
GLUT 1 aka
SLC2a1
AGGTGTCACCCACAGCTCTT
Tm=59.4ºC GC Content=55%
Length=20bp
AGAGGCCACAAGTCTGCATT
Tm=57.3ºC GC Content=50%
Length=20bp
GLUT 4 aka
Slc2a4
TCCCTTCAGTTTGGCTATAACATTG
Tm=59.7ºC GC Content=40%
Length=25bp
CTACCCAGCCAAGTTGCATTG
Tm=59.8ºC GC Content=52.4%
Length=21bp
GR aka Nr3c1 GTCAGAACTGGCAACGGTTT
Tm=57.3ºC GC Content=50%
Length=20bp
TCCAAAAATGTCTGGAAGCA
Tm=53.2ºC GC Content=40%
Length=20bp
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2.5 Statistical Methods
Data is shown as the mean r SEM throughout the thesis. SPSS (version 15.0/16.0)
was used to complete all analyses. Results were considered statistically significant
when P<0.05.
Coefficient of Variation
Intra-assay coefficient of variation was calculated to compare data from duplicate
samples on the same plate.
Inter-assay coefficient was calculated to compare data from the same sample on
different plates.
CV (%) = Standard Error x 100
Mean
Baseline/Day 0 (10 days in culture) data for both trial one and two was analysed using
an independent t-test looking at the difference between the two diet groups. Each
endpoint measurement was analysed separately against diet. Day 2 (12 days in
culture) data for both trial one and two was analysed using a two way ANOVA looking
at significance of diet and dexamethasone on cultures, using an LSD test for post hoc
analysis. Baseline and Day 2 data were analysed separately and not statistically
compared.
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3 Chapter 3
Results
3.1 Trial One  Impact of maternal protein restriction on neonatal
cardiomyocyte glucose uptake.
The aim of this trial was to identify responses of neonatal cardiomyocytes to
increasing concentrations of dexamethasone in culture. Ten pregnant females were
fed either a control (n=5) or low protein, MLP, (n=5) diet during gestation and
neonatal hearts were used to culture cardiomyocytes. These cultures were grown for
ten days, at which point some were taken to complete baseline analysis, and others
were treated with different concentrations of dexamethasone (0, 100nM and 10µM),
and left for a further 48 hours (day 2 cells) before analyses.
Maternal weight gain and food intake were measured throughout gestation. Neonatal
cardiomyocytes were cultured and used for the analysis of protein concentration, DNA
concentration, glucose uptake and cell number, including percentage of
mononucleated and binucleated cells, for all time points. Cells were challenged with
dexamethasone to examine responsiveness to glucocorticoids.
3.1.1 Maternal weight gain and litter sizes
Low protein females appeared to consume more during pregnancy compared to
controls, but this was found to not be significantly different. Maternal weight gain and
litter size were also found to not be affected by diet during pregnancy (Table 3.1).
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3.1.2 Cell Counts
Cell count was used in this study as a measure of cell proliferation. Cell counts were
completed on duplicate wells from each litter at both time points, and for all three
treatment stages.
All cultures were seeded at a density of 100,000 cells/ml/well in 24-well plates. As
shown in Figure 3.1, baseline counts (i.e. day 11) tended to be higher in MLP cultures
in comparison to controls. However, an independent t-test found no significant
difference between the dietary groups. Cell number decreased in MLP cultures after 2
days of Dex treatment, but in controls remained unaffected. There appeared to be a
slight effect of the increasing Dex concentration in both groups, but a two-way ANOVA
showed no significant effects.
Figure 3.1 - Cell count of control and MLP cultured cardiomyocytes
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See Table 3.1 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
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Table 3.1 - Maternal weight gain, food intake and litter sizes
Maternal Diet Control Low Protein P value
N 5 5
Initial weight (g) 232.1
r 8.9
235.9
r 8.4
NS
Final Weight (g) 327.7
r 18.6
334.3
r 10.5
NS
Weight Gain
GA 1-7 (g)
28.9
r 1.8
33.1
r 2.9
NS
Weight Gain
GA 8-14 (g)
27.6
r 3.9
35.0
r 5.2
NS
Weight Gain
GA 15-21 (g)
41.7
r 5.0
43.2
r 3.2
NS
Food Intake (g) 410.2
r 34.2
489.3
r 13.1
NS
Food Intake
GA 1-7 (g)
167.6
r 8.8
195.7
r 8.0
NS
Food Intake
GA 8-14 (g)
135.6
r 20.8
166.9
r 5.5
NS
Food Intake
GA 15-21 (g)
107.0
r 13.2
127.6
r 6.2
NS
Litter Size 11.2
r 1.0
9.8
r 0.9
NS
Pregnant dams were fed either a control (18% casein) or low protein (MLP, 9% casein) diet throughout
gestation. Eight neonates per litter were culled on day of parturition, when their hearts were dissected out.
Cardiomyocytes were cultured for 10 days. At this point some were treated for 48 hours with increasing
concentrations of dexamethasone. Data is shown as a mean r SEM for n litters. An independent t-test
showed that there was no significant effect of diet on maternal food intake, weight gain or litter size. NS,
not significant.
3.1.3 Binucleated and Mononucleated cell number
Cell staining to identify the number of mononucleated and binucleated cells was
completed to assess the stage of cell differentiation. Immature cardiomyocytes will
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tend to be mononucleated, but in the mature heart we would expect to see a greater
proportion of binucleated cells (Corstius et al., 2005). Table 3.2 shows that overall
there was a greater number of mononucleated cells in comparison to binucleated cells
across all time points and treatment groups. This indicates that the cardiomyocytes
were still dividing and proliferating in the cultures. It was noted that there was no
effect of diet on the proportions of mononucleated and binucleated cells at baseline.
This is consistent with the findings of Corstius et al. (2005). However, maternal diet
did have a statistically significant effect on the number of mononucleated and
binucleated cells in dexamethasone treated cultures. Treatment of the cells with
dexamethasone per se, did not significantly impact upon the proportion of mono- and
binucleated cells. However, ANOVA indicated a significant effect of maternal diet
(P<0.05) in the Dex treated cells. Cultures from MLP litters had a significantly greater
proportion of binucleated cells, particularly in cultures treated with 100nM Dex.
Table 3.2  Effect of diet and Dex on proportions of binucleated and mononucleated
cells
Day Diet Dex
treatment
%
Mononucleated
Cells
SE %
Binucleated
Cells
SE
Baseline Control 0 90 1.8 9 1.5
MLP 0 93 1.7 7 1.7
Day 2 Control 0 94 1.1 6 1.1
100nM 91 2.6 9 2.7
10µM 92 1.6 8 1.6
Day 2 MLP 0 87* 3.7 13* 3.7
100nM 83* 4.9 17* 4.9
10µM 87* 3.6 13* 3.6
See Table 3.1 for full legend. Data is shown as a percentage mean r SEM for cells taken at Day 0 and 2 of
culture growth and treatment. There was no significant effect of diet on baseline cultures. A two-way ANOVA
showed that there was a significant effect of diet on the percentage of mononucleated and binucleated cells
at day 2 (P=0.042), but no effect of dexamethasone. * indicates the significant difference between control
and MLP.
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3.1.4 Protein Concentration
Protein concentration in the cardiomyocyte cultures was used as a proxy for cell size.
As shown in Figure 3.2, diet did not affect the protein content of the cells after ten
days in culture (baseline). Baseline protein content however was approximately double
the concentration observed in all dexamethasone treated cells. A two-way ANOVA of
the protein content of cells after two further days in culture showed no statistical
effect of diet or Dex treatment.
Figure 3.2 - Protein content in cell cultures from control or MLP treated rats.
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See Table 3.1 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
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3.1.5 DNA Concentration
DNA concentration was measured, alongside the cell counts, to assess cell proliferation
in the cardiomyocyte cultures when exposed to different Dex treatments. As shown in
Figure 3.3, there was no baseline data available. This was because the DNA
concentrations of these cultures were below the detection limits of the assay.
Untreated day 2 cultures in the control diet group appeared to have an increased DNA
content in comparison to 100nM and 10µM Dex cultures. DNA content in the MLP
group remained consistent, and it was found that overall the DNA concentration was
not affected by maternal diet or Dex treatment.
Figure 3.3 - DNA concentration of day 2, treated neonatal cardiomyocyte cultures
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See Table 3.1 for full legend. Data is shown as a mean r SEM. A two-way ANOVA indicated that there was
no significant effect of diet or dexamethasone treatment on the cells.
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3.1.6 DNA:Protein Ratio
The DNA:protein ratio (Figure 3.4) was calculated by dividing DNA content by protein,
and this was calculated to give a further indication of cell size. The higher the ratio,
the larger the cells and vice versa. Due to the DNA baseline data being below the
fluorescence detection limit, a ratio for baseline cells could not be calculated. A two-
way ANOVA showed no statistical effect of either diet or Dex treatment on the
DNA:protein ratio in the cardiomyocyte cultures. However, there did appear to be a
slight trend, as the Dex concentration increased, the DNA:protein ratio decreased
(NS).
Figure 3.4 - DNA:Protein Ratio of day 2, treated neonatal cardiomyocyte cultures
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See table 3.1 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells.
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3.1.7 Protein:cell count Ratio
Protein:cell count ratio (Figure 3.5) was calculated as an alternative indication of cell
size. A two-way ANOVA showed no statistical effect of either diet or Dex treatment on
the protein:cell count ratio in the cardiomyocyte cultures. However, for MLP cells in
the day 2 cultures, this measure appeared to increase with Dex treatment, whereas
baseline cells tended towards a higher ratio in control compared to MLP (NS).
Figure 3.5 - Protein:cell count ratio in control and MLP cultures
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See table 3.1 for full legend. Data is shown as a mean r SEM and expressed as protein:cell count ratio per
million cells. There was no significant effect of diet or dexamethasone treatment on the cells.
3.1.8 Glucose Uptake Assay
Glucose uptake was determined to gauge the metabolic activity of the cardiomyocyte
cells in culture. It demonstrated the metabolic function of the cells, their demand for
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and uptake of glucose, which is the main energy source required to power cellular
processes. Uptake was expressed as pmole/hour/million cells, and was determined in
both the basal and insulin stimulated state.
At baseline, basal glucose uptake appeared to be greater in the control cultures
compared to the MLP cultures as shown in Figure 3.6A; however an independent t-test
showed no significant effect of diet. Basal glucose uptake at day 2 was also found to
be unaffected by diet. Although uptake appeared increased by Dex treatment at both
doses, this affect did not achieve statistical significance.
Figure 3.6A - Day 0 and Day 2 basal glucose uptake in control and MLP neonatal
cardiomyocyte cultures
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See Table 3.1 for full legend. Data is shown as a mean (expressed as pmole/hour/million cells) r SEM. An
independent t-test and two-way ANOVA showed that there was no significant effect of diet or
dexamethasone treatment on the cells.
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Insulin stimulated glucose uptake (Figure 3.6B), at the baseline time point was similar
in the two diet groups. At day 2 however, insulin stimulated glucose uptake was found
to be affected by both diet (P<0.05) and Dex treatments (P<0.05), but there was no
interaction between the two. As shown in Figure 3.6B, in the absence of
dexamethasone (Day 2, 0 Dex), insulin stimulated glucose uptake was lower in the
MLP groups than control (approximately 21% lower, P<0.05). Dexamethasone
treatment at either dose increased insulin stimulated glucose uptake. This effect was
exaggerated in the MLP cultures with a 4-fold increase noted at 10µM Dex, compared
to just 27% increase in the control cultures. In Dex treated cultures insulin stimulated
glucose uptake was markedly higher in MLP than in the control group.
Figure 3.6B - Day 0 and day 2 insulin-stimulated glucose uptake in control and MLP
neonatal cardiomyocyte cultures
See Table 3.1 for full legend. Data is shown as a mean (expressed as pmole/hour/million cells) r SEM. A
two-way ANOVA showed that there was a significant effect of diet (P=0.03) and Dex (P=0.013)
(independently) on the insulin stimulated glucose uptake. § indicates the significant difference between 0
Dex and 10µM treated cells.
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3.2 Trial Two  Impact of maternal protein restriction on neonatal
cardiomyocyte gene expression.
For the second trial, ten pregnant females were fed either a control (n=5) or low
protein (n=5) diet during gestation and neonatal pup hearts obtained to culture
cardiomyocytes. These cultures were grown for ten days when some were taken to
complete baseline analysis, and other cultures were treated with different
concentrations of dexamethasone (0, 10nM and 100nM), and left for a further 48
hours (day 2 cells) before analysis.
Maternal weight and food intake were measured throughout gestation. Neonatal
cardiomyocyte cells were cultured and used for the analysis of protein and DNA
content, glucose transporter expression, cell death and cell number, including
percentage of mononucleated and binucleated cells, for all time points. As with the
first trial, glucocorticoid response was assessed by challenging cells with varying
concentrations of dexamethasone. In trial one, cells were treated with one
concentration that was within physiologically range, 100nM, and the second dose,
10µM, was selected with the intention of eliciting maximal responses. In this trial, both
concentrations were selected to be within the physiologically relevant range.
The results from trial one showed that there was an effect of diet and Dex on insulin-
stimulated glucose uptake. Due to this finding, mRNA expression of GLUT 1, GLUT 4,
and glucocorticoid receptor (GR) was investigated to see if changes in gene expression
could explain increased glucose uptake when cardiomyocytes are stimulated with
insulin. Additionally, cell death in the cardiomyocyte cultures was investigated by
running a cell death ELISA, and determining the ratio of dead and live cells.
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3.2.1 Maternal weight gain and litter sizes
Maternal weight gain, total food intake and litter size were not affected by the diet fed
during pregnancy (Table 3.3). Weekly food intake was also not significantly affected
by maternal diet.
3.2.2 Cell Count
In this trial, cell count was completed using the Trypan blue method to identify dead
and live cells. Total cell count was a sum of these two measurements per cell culture
well. As with the first trial, all cultures were seeded at a density of 100,000
cells/ml/well in 24-well plates, and were measured in duplicate for both time points
and all treatment groups.
As shown in Figure 3.7 all counts were similar across diet groups and Dex treatments,
with MLP counts being slightly lower compared to control. An independent t-test
showed no significant effect of diet on the total cell count at the baseline stage (after
10 days in culture). There was no significant effect of diet or Dex, and no interaction
between the two, in day 2 cells. However, cell counts in this trial were higher in
comparison to the first trial (Figure 3.1).
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Table 3.3  Maternal weight gain, food intake and litter size
Maternal Diet Control Low Protein P value
N 5 5 /
Initial weight (g) 226.8
r 6.1
211.2
r 5.2
NS
Final Weight (g) 312.2
r 7.6
302.2
r 10.0
NS
Weight Gain
GA 1-7 (g)
19.4
r 3.8
27.5
r 3.2
NS
Weight Gain
GA 8-14 (g)
23.0
r 2.8
22.4
r 1.7
NS
Weight Gain
GA 15-21 (g)
47.2
r 3.2
55.1
r 12.2
NS
Food Intake (g) 431.6
r 16.5
420.8
r 10.5
NS
Food Intake
GA 1-7 (g)
152.5
r 3.9
150.5
r 7.3
NS
Food Intake
GA 8-14 (g)
126.5
r 10.0
144.8
r 2.6
NS
Food Intake
GA 15-21 (g)
152.7
r 10.3
125.4
r 7.1
NS
Litter Size 8.0
r 1.0
10.0
r 1.0
NS
Pregnant dams were fed either a control (18% casein) or low protein (MLP, 9% casein) diet throughout
gestation. Eight neonates per litter were culled on day of parturition, when their hearts were dissected out.
Cardiomyocytes were cultured for 10 days. At this point some were treated for 48 hours with increasing
concentrations of dexamethasone. Data is shown as a mean r SEM for n litters. An independent t-test
showed that there was no significant effect of diet on maternal food intake, weight gain or litter size. NS,
not significant.
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Figure 3.7 - Total cell count in cultures of neonatal cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.3 Dead and Live cell counts
Using the trypan blue method as detailed in Chapter 2, cells were counted, identifying
dead and live cells per cell culture well. There was no significant effect of either diet or
dexamethasone on the proportions of live to dead cells (Figure 3.8). Performing the
cell counts with trypan blue indicated that between 35% and 65% of cells in culture
were dead. There was a tendency for fewer cells to survive in the MLP cultures, but
this did not achieve statistical significance.
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Figure 3.8 - Dead and live cell counts of control and MLP cultured cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.4 Mononucleated and binucleated cell counts
Table 3.4 shows that most cardiomyocytes in culture were mononucleated, indicating
that cells were still dividing and were not fully differentiated. The percentage of
binucleated cells across both days and treatment groups were very similar. Maternal
diet had no effect on baseline cultures, and an ANOVA of day 2 cultures indicated that
differentiation was not affected by diet or Dex treatment.
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Table 3.4  Effect of diet and Dex on proportions of binucleated and mononucleated
cells
Day Diet Dex
treatment
%
Mononucleated
Cells
SE %
Binucleated
Cells
SE
Baseline Control 0 91 1.3 9 1.3
MLP 0 92 1.1 8 1.1
Day 2 Control 0 92 1.0 8 1.0
10nM 90 1.4 10 1.4
100nM 94 0.8 6 0.8
Day 2 MLP 0 92 1.2 8 1.2
10nM 90 1.5 10 1.5
100nM 91 1.1 9 1.1
See Table 3.3 for full legend. An independent t-test showed that diet had no significant effect on the
percentage of mono and binucleated cells at the baseline level. Dexamethasone treated cells were also not
affected by diet or dex, and there was no interaction between the two. NS, not significant.
3.2.5 Protein Concentration
As shown in Figure 3.9, diet did not affect the protein content of the cells after ten
days in culture (baseline). Baseline protein concentration was approximately double
the concentration observed in all dexamethasone treated cells. A two-way ANOVA of
the cells after two further days in culture showed no statistical effect of diet or Dex
treatment.
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Figure 3.9  Protein concentration of control and MLP cultured cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.6 DNA Concentration
DNA concentration was measured to assess cell proliferation rates of cells in response
to Dex treatment. Overall, the cardiomyocytes DNA concentration was quite low,
suggesting that the samples were falling towards the lower end of the detection limit.
As shown in Figure 3.10, DNA concentration in the baseline cultures was found to not
be affected by diet. Day 2 MLP cultures appeared to show an increase in DNA
concentration with increasing Dex treatment but this effect of diet did not achieve
statistical significance (P=0.06).
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Figure 3.10 - DNA concentration of control and MLP cultured cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.7 DNA:Protein Ratio
DNA:Protein ratio was calculated by dividing DNA content by protein to give an
indication of cell size. As seen in Figure 3.11 the baseline ratio was almost half of that
seen in day 2 cultures. An independent t-test found that diet had no significant effect
on the ratio at any level. However, the P-value for baseline cultures was 0.065
suggesting that there is a trend in the data. In the day 2 control cultures the ratio
appeared to be fairly consistent in comparison to MLP litters where the ratio increased
with Dex increments. ANOVA showed no significant affect of either diet or Dex, and no
interaction between the two.
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Figure 3.11 - DNA:protein ratio of cultured neonatal cardiomyocytes
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See Table 3.1 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.8 Protein:Total Cell Count Ratio
Protein:total cell count ratio was calculated as another indicator of cell size. The ratio
was expressed as protein:total cell count per million cells.
Baseline data appeared to be approximately double that of the day 2 treated cells
(Figure 3.12). There was no significant effect of diet or dexamethasone treatment
upon protein concentration noted at either time point.
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Figure 3.12 - Protein:total cell count ratio of control and MLP cultured
cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM, and expressed as protein:total cell count
ratio per million cells. There was no significant effect of diet or dexamethasone treatment on the cells at any
time point.
3.2.9 Protein:Live Cell Count Ratio
Protein:live cell count ratio was another indicator of cell size and was expressed as
protein:live cell count per million cells. As with the total cell count ratio, the baseline
data was approximately double that of the day 2 treated cells, but was not
significantly affected by diet (Figure 3.13). Protein:live cell count ratio showed a
similar pattern to that seen for the protein:total cell count ratio in all days and
treatments except for 0 Dex. Day 2 cultures were found to be significantly affected by
diet (P=0.041), with control showing a higher ratio in comparison to MLP for the
treated cells. Dexamethasone was found to have no effect upon protein:live cell ratio
in these cultures.
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Figure 3.13 - Protein:live cell count ratio of control and MLP cultured cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM and expressed as protein:live cell count ratio
per million cells. There was no significant effect of diet at the baseline level. Day 2 cells were not affected by
dex, but were significantly affected by diet (P=0.041).
3.2.10 Cell Death
Cell death is a measure of the number of cells dying in culture, and was used to
monitor the response of the cells to the Dex treatments. Cell death was expressed as
a ratio against the QC absorbance.
It was found that diet and Dex had no effect on cell death in cultures across any time
point or treatment group. It did appear that control cultures have less cell death than
MLP (Figure 3.14), but this was not found to be significant.
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Figure 3.14 - Cell death ratio of control and MLP neonatal cardiomyocytes
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.11 Gene expression
Glucose transporter 1 (GLUT 1), glucose transporter 4 (GLUT 4), and glucocorticoid
receptor (GR) mRNA expression was determined by RT-PCR to investigate the
response of cardiomyocytes to Dex treatment, and assess whether altered expression
of these genes was the reason for the increased glucose uptake in insulin-stimulated
cardiomyocytes noted in trial one.
Cells were seeded at 200,000 cells per well in 12 well cell culture plates and grown
and treated under the same conditions as cells seeded in 24 well plates. Data was
normalised to Cyclophilin A, as a housekeeper gene, which was found to have
consistent expression across diet groups in baseline cells, and across all Dex
concentrations at day 2 (Figure 3.15)
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Figure 3.15 - Cyclophilin A mRNA expression of neonatal cardiomyocyte cultures
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See Table 3.3 for full legend. Data is shown as a mean r SEM. There was no significant effect of diet or
dexamethasone treatment on the cells at any time point.
3.2.11.1 GLUT 1
As shown in Figure 3.16, mRNA expression of baseline GLUT 1 was not significantly
affected by maternal diet. GLUT 1 expression in day 2 cultures was fairly consistent
across treatment groups and an ANOVA found no significant affect of either diet or
Dex treatment.
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Figure 3.16 - GLUT 1 mRNA expression of neonatal cardiomyocyte cultures.
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See Table 3.3 for full legend. Data is shown as a mean r SEM, and normalised to Cyclophilin A, housekeeper
gene. There was no significant effect of diet or dexamethasone treatment on the cells at any time point.
3.2.11.2 GLUT 4
At the baseline stage, an independent t-test found no significant affect of diet on
cultures (Figure 3.17). Day 2 cultures also showed no affect of diet, but
dexamethasone treatment was found to significantly impact upon GLUT 4 mRNA
expression (P=0.008). ANOVA showed that 0 Dex cells had a greater expression of
GLUT 4 in comparison to 10nM and 100nM treated cultures, with a more marked
difference seen at 100nM Dex.
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Figure 3.17 - GLUT 4 mRNA expression of neonatal cardiomyocyte cultures
See Table 3.3 for full legend. Data is shown as a mean r SEM, and normalised to Cyclophilin A housekeeper
gene. There was no significant effect of diet at the baseline level, and no effect of diet on day 2 cells. *
indicates significant difference between 0 Dex and 10nM (P=0.018),  indicates a significant difference
between 0 Dex and 100nM (P=0.003), no significant difference between 10nM Dex and 100nM Dex.
3.2.11.3 Glucocorticoid Receptor
From baseline cells through to 100nM Dex treated cells the expression of GR mRNA
increased steadily (Figure 3.18).
An independent t-test showed no significant effect of diet on GR expression in the
baseline cells. ANOVA indicated no effect of diet and no interaction between diet and
Dex on day 2 cells, but Dex had a significant affect on the expression of GR
(P=0.009). GR expression was significantly higher in the 100nM Dex treated cultures
than in 0 or 10nM cultures (P<0.05), but the lower dose did not significantly increase
expression over the untreated cultures.
0.000
0.500
1.000
1.500
2.000
2.500
3.000
3.500
4.000
4.500
0 Dex 10nM Dex 100nM Dex
Baseline Day 2
Day and Dexamethasone Treatment
G
L
U
T
4
:C
y
c
lo
p
h
il
in
A
a
rb
it
ra
ry
u
n
it
s
Control
MLP
* 
* 
91
Figure 3.18 - Glucocorticoid receptor mRNA expression of neonatal cardiomyocyte
cultures
See Table 3.3 for full legend. Data is shown as a mean r SEM, and normalised to Cyclophilin A housekeeper
gene. There was no significant effect of diet at the baseline level, and no effect of diet on day 2 cells. 
indicates significant difference between 0 Dex and 100nM (P=0.003), § indicates a significant difference
between 10nM Dex and 100nM (P=0.028).
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4 Chapter 4
Discussion
The fetal programming hypothesis suggests that nutritional deficiencies during fetal
development predispose offspring to develop cardiac abnormalities in later life
(Campbell et al., 1996, Godfrey et al., 1996, Godfrey & Barker, 2000). Human cohort
studies have provided evidence to suggest that undernutrition causes growth
retardation (Sydall et al., 2005, Campbell et al., 1996), which is a precursor of
cardiovascular disease. However, there are numerous criticisms of the epidemiological
evidence, so animal models have been designed to further investigate human findings.
They provide the opportunity to explore in more detail the mechanisms that are
associated with changes.
The aims of this thesis were to investigate the effects of maternal low protein (MLP)
diet on offspring heart structure and function. This model of maternal protein
deficiency was developed in the rat by Langley & Jackson (1994), and is a well-
established tool for the investigation of nutrient restriction as a contributor to the
onset of cardiovascular disease in offspring in adult life (Langley-Evans et al., 1999,
Harrison & Langley-Evans, 2008). Hypertension in rodent offspring is one outcome of
this diet and has been investigated extensively (Langley & Jackson, 1994, Langley-
Evans et al., 1994, Langley-Evans et al., 1996, Langley-Evans et al., 1999). Studies
have moved on to investigate specific effects of programming on cardiomyocytes.
They have found that a low protein diet affects various aspects of heart structure and
function, including a decrease in the contractile ability of the heart (Cheema et al.,
2005), evidence of hypertrophy (Cheema et al., 2005, Oparil, 1984), a reduction in
cell nuclei number (Corstius et al., 2005), and left ventricle wall thickening (Cheema
et al., 2005) as well as impaired recovery of left ventricle pressure following ischemic
reperfusion (Elmes et al., 2007). Using primary cultures of neonatal cardiomyocytes
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exposed to MLP diet in utero, this study investigated if the effects of this diet in
cultured cells mimic those seen in animal studies. It also began to explore if synthetic
glucocorticoids have programming effects on glucose uptake and the expression of
related genes.
4.1 Maternal Effects
In trial one, although MLP animals consumed more during pregnancy it was not
significantly different. Similarly in trial two, maternal total food intake during
pregnancy was not affected by diet. MLP females may be attempting to increase
protein intake by consuming more, but Langley & Jackson (1994), who also noted
slight increase in food intake in MLP fed female rats, found that the compensation was
not sufficient to offset the protein restriction. In a normal rat pregnancy pre-
implantation and implantation occurs in week one (embryonic phase), followed by an
organogenesis phase in week two, and finally rapid growth, differentiation and
maturation of the fetus in the final week (Bellinger et al., 2005). Due to this, it was
thought that the rats would consume more food during the final week of gestation.
This current study has similar findings with other studies, which also found that food
intake was not affected by the low protein diet (Langley-Evans et al., 1994, Cheema
et al., 2005, Tappia et al., 2005).
Maternal weight gain was also not affected by MLP diet in either trial, which is
comparable with Langley-Evans et al. (1994) who noted no difference in maternal
weight gain between the two diet groups. Heywood et al. (2004) saw a 14.9%
decrease in low protein fed females weight during pregnancy compared to controls.
The low protein diet was however a slightly different composition, made up of 6%
protein compared to the 9% casein model used in this study. Comparable to other
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studies (Langley & Jackson, 1994, Langley-Evans et al., 1994, Corstius et al., 2005)
litter size did not differ between the dietary groups in either trial.
4.2 Cardiomyocyte Characteristics
Cell counts were not significantly affected by diet or dexamethasone treatment across
any time point in either trial, and remained at a steady count across both day 0 and 2
cultures. There was no decline in counts from day 0 to 2 demonstrating that cultures
were not dying. Interestingly, counts were quite varied across the trials, trial two
cultures had an overall higher number of cells compared to trial one. Trial two counts
were approximately 200,000 cells/ml, and trial one counts were between 8000 and
12,000 cells/ml. The reason for these differences could be due to improvement on
technique of isolating and culturing primary cells, or inter-litter variability. Trial two
counts did appear to show a possible trend whereby MLP counts were slightly lower to
that seen in control. This is similar to the findings in the Corstius et al. (2005) study,
where offspring exposed to a low protein diet during gestation had a decreased
number of cardiomyocytes (1.15x107) compared to control animals (1.43x107).
Live cell counts and apoptosis were assessed and found to be not significantly different
between control and MLP diets. There did appear to be a possible trend, with MLP
cultures having a higher apoptosis rate compared to controls, and more dead cells
than live. Further investigation of this trend may be worth pursuing as Cheema et al.
(2005) reported maternal low protein diet increased cardiomyocyte apoptosis by
three-fold in five day old neonates. Apoptosis and necrosis are both types of cell death
that differ in morphology, mechanism and incidence (Dive et al., 1992). The Roche cell
death ELISAPLUS kit used in this thesis measured cytoplasmic histone-associated DNA
fragments, which occurs in apoptosis several hours before plasma membrane
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breakdown. Apoptosis is natural cell death where cells shrink, and condensation of
cytoplasm occurs, activating endogenous endonuclease which cleaves systemic DNA
(Dive et al., 1992, Roche, UK). Phagocytes then rapidly engulf these cells preventing
inflammatory responses from occurring. For these reasons it is complicated to
measure (Dive et al., 1992). Necrosis is the death of living tissue through disease,
injury, or disruption of blood supply. The cell membrane is disrupted, which leads to
respiratory poisons and hypoxia causing depletion of ATP, loss of metabolic function,
and the cell swells and ruptures leading to inflammation. Future studies could measure
ATP concentrations in the cells, or markers of inflammation to assess if MLP diet
causes tissue damage leading to cell death. The Roche cell death ELISAPLUS can also be
used to measure necrosis instead of apoptosis. Dive et al. (1992) suggest an
alternative method for quantifying apoptosis and necrosis. Multi-parameter flow
cytometry measures cell diameter, internal granularity and DNA binding, which has
been suggested as a more accurate measure of cell death.
Another alternative measure of cell death is determining apoptosis specific gene
expression by western blot or immunohistochemistry (Condorelli et al., 1999). Bcl2-
associated X protein (Bax) is a pro-apoptotic gene that has been shown to be up-
regulated in ischemic myocardium in vivo. E-cell lymphoma 2 (Blc-2) is an anti-
apoptotic gene that under the same circumstances has been shown to be decreased
(Condorelli et al., 1999). They both lie upstream in the cell death pathway and play an
important role in whether a cell will die (Gross et al., 1999). The ratio of the two
genes has been suggested to be an important marker of myocardial cell survival
probability (Condorelli et al., 1999). Caspases lie further down-stream to Bax and blc-
2 in the apoptosis pathway, and could also be measured as they play an essential role
in cell apoptosis.
Fully differentiated cardiomyocytes are binucleated, and immature cells are
mononucleated. In both trials, a greater number of mononucleated cells were seen
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compared to binucleated across both dietary groups, indicating that all cultures
contained cells which were immature and actively proliferating. In trial one and two,
nucleation in baseline cultures was unaffected by diet. In day 2 cultures however, MLP
exposure decreased the percentage of mononucleated and increased binucleated cells
compared to controls. This suggested that at day 2 MLP diet led to an increased
number of fully differentiated cardiomyocytes compared to control cultures. This
finding did not appear to be robust however, as in trial two there was no effect of diet
on the day 2 cultures. Dexamethasone treatment did not affect the number of nuclei
in either trial, demonstrating that, in this study, glucocorticoids had no effects
postnatally on cell differentiation in culture. Corstius et al.s (2005) study using the
MLP model also found that dexamethasone administered, postnatally, had no effect on
nucleation of cardiomyocytes. Consistent with this current study, Corstius et al. (2005)
found binucleation to be low across both diet groups, but no differences were noted
between the control and low protein diets. De Vries et al. (2002) reported an increase
in myocyte volume, indicative of hypertrophy in rats administered dex in the first
three days of neonatal life.
For both trials protein content was not significantly affected by diet or dex at either
time point. De Vries et al. (2002) investigated protein concentration in left and right
ventricles in neonates exposed to standard chow diet during gestation, and
administered dexamethasone at days 1, 2 and 3 postpatrum. In 7 day old pups,
protein tended to be higher in dexamethasone treated animals compared to saline.
Interestingly, in this current study, in both trials, baseline cultures had almost double
the protein concentration in comparison to the dexamethasone treated cells. This data
was not statistically compared, but a possible reason for the noted difference could be
due to a lack of fetal bovine serum (FBS) in the growth medium in day 2 cultures. FBS
was not added to day 2 culture medium in order to measure the direct effects of
dexamethasone without FBS and other medium additives interfering. For future
studies, it would be interesting to measure cell proliferation in cultures that have been
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grown in medium with and without serum, as it contains growth factors that promote
cell proliferation (Sigma, UK).
De Vries et al. (2002) also calculated the protein:DNA ratio as an indicator of cell size,
and found the ratio to be higher in dexamethasone treated rats compared to saline
treated rats at 7 days old. The higher the ratio the larger the cells and vice versa, so
the finding suggested that dexamethasone treated animals had larger cells, indicative
of hypertrophic growth. Protein:DNA ratio and protein:total cell count ratio were
calculated in the current trial, but were not affected by diet or dexamethasone.
Protein:live cell count ratio was calculated in trial two and was significantly, but
inconsistently affected by MLP diet in day 2 cultures. Even though Dex treatment had
no significant effect, untreated day 2 cultures established an increased ratio in the
MLP litters in comparison to control, and the opposite was seen in untreated litters.
The high ratio seen in untreated MLP cultures indicates larger cells and the low ratio in
the MLP treated cultures indicates smaller cells. The reason for this difference is
unknown.
Various in vivo studies have found MLP diet leads to functional defects in the hearts of
offspring in the first few weeks of life. Cheema et al. (2005) noted a severe depression
in ejection fraction (left ventricular end-diastolic volume) of the heart in the first 2
weeks of neonatal life, with the greatest peak depression seen in 7 day old pups. From
1 to 84 days of age, MLP offspring exhibited increased left ventricular internal
diameters during systole and diastole, as well as thinner walls from 3 days to 2 weeks
of age, where thickening began and continued into adult life (Cheema et al., 2005).
De Vries et al. (2002) also noted changes in heart structure and function in 7 day old
pups. Heart weight and DNA content was lower compared to controls, with higher
protein content and protein:DNA ratio. The mitotic index of cardiomyocytes was low at
birth in MLP animals, but then increased one to two weeks postpartum (Aroutiounova
et al., 2009). The earliest onset of hypertension however, has been noted in 4 week
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old rat pups (Langley-Evans et al., 1994). Functional changes in rat offspring hearts
exposed to MLP in utero, appear to occur after one week old, and disease state occurs
later in life. This suggests that these changes are not a product of a diseased heart,
and cultures in this study would not be at a diseased stage.
The measures of cell proliferation assessed in the current study partly address the
hypothesis set that MLP diet affects proliferation and differentiation rates. This diet, in
some, but not all cases, had an effect on cardiomyocyte cultures demonstrating that it
had programming effects on cell growth, proliferation and differentiation, some of
which are similar to those seen in vivo.
4.3 Glucose uptake and gene expression
Glucose uptake, a measure of cellular function, was not affected by diet or
dexamethasone at the basal level, but was affected by dexamethasone treatments
when stimulated with insulin. Baseline (Day 0) insulin stimulated glucose uptake was
not influenced by maternal diet, but both diet and dexamethasone impacted on day 2
cultures. Following treatment with 10µM dexamethasone for 48 hours, the cultures
had an increased glucose uptake in response to insulin stimulation. 100nM of
dexamethasone on the other hand, had no effect. The effects of insulin stimulation in
the 10µM dexamethasone treated cells were exaggerated in the MLP cultures, which
indicates that these cultures are more sensitive to Dex. This suggests that
glucocorticoids elicit enhanced responses in MLP cardiomyocytes compared to control,
causing them to take up more glucose when insulin is present. This supports the
hypothesis that maternal protein restriction increases sensitivity to synthetic
glucocorticoids in cultured cardiomyocytes, but only with concentrations above the
physiological range. Maternal low protein cultures treated with 100nM dex did not
show an increased sensitivity. This is consistent with in vivo findings of maternal
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protein deficiency, which in utero lead to the offspring developing glucocorticoid
sensitivity (Langley-Evans & Nwagwu, 1998, Langley-Evans et al., 1996b).
Overexposure of the fetus to maternal glucocorticoids is thought to be due to
decreased expression of placental 11ǃ-HSD-2, which protects the fetus from maternal
GCs (Drake & Seckl, 2004, Benediktsson et al., 1993). MLP diet is known to decrease
placental 11ǃ-HSD-2, leading to increased sensitivity of the offspring to circulating
glucocorticoids (Langley-Evans et al., 1996). Langley-Evans et al. (1996b) found an
increased activity of corticosterone-sensitive enzymes related to low hormone
concentrations and increased GR binding capacity and receptor numbers in the
hippocampus of MLP male offspring.
Another possible reason for the increase in glucose uptake is that dexamethasone
inhibited the final stages of hyperplastic growth, leading to the cardiomyocytes
requiring a higher energy intake to undergo hypertrophic growth. Findings from cell
proliferation and differentiation however, were not consistent enough to conclude this.
The increased glucose uptake appears more likely to be mediated by the altered
expression of glucocorticoid receptor leading to GC sensitivity from the low protein
diet.
One hypothesis to be addressed by this study was that maternal undernutrition alters
the expression of genes involved in regulating glucose uptake. Glucose transporter
expression was measured to test this hypothesis, and given the response of insulin-
stimulated glucose uptake to dexamethasone it was also of interest to determine
whether the glucose transporters were regulated by glucocorticoids. Baseline GLUT 1
expression in MLP and control cultures were not dissimilar. Day 2 treated cultures also
showed no significant difference and GLUT 1 expression was constant across all Dex
treatments. Interestingly in day 2 cultures, expression of GLUT 1 was approximately
25% higher in both MLP and control groups, in comparison to baseline. Baseline and
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day 2 data though, were not statistically compared, but the increase in expression
suggests that day 2 cells were undergoing a higher rate of hypertrophic growth. The
reason for this however, is unknown. Conversely, Langdown et al. (2001), found that
dexamethasone administered mid-gestation increased the expression of GLUT 1 in
adult offspring. It was thought that this increase was not a direct cause of
dexamethasone, but the hypertension that dexamethasone caused, possibly through
altered Akt/protein kinase B pathways.
There was a clear theme throughout the whole study that baseline/day 0 cultures (10
days in culture) differed to day 2, 0 Dex cultures (12 days in culture). The only
difference between the methods of culturing was the medium mixture used. All
cultures were grown in a DMEM mix containing FBS, P/S and fungizone until 10 days
in culture (baseline/day 0). Day 2 cultures then had DMEM added, containing either no
dexamethasone or the two different concentrations. This is possibly the reason for the
difference seen between the two groups, and as mentioned previously, it would be
interesting in future studies to culture cardiomyocytes with and without FBS to identify
if it affects proliferation rates and other parameters of interest.
Glucose transporter 4 (GLUT 4) expression was not affected by maternal protein
restriction in the baseline cultures. Day 2 cultures were also not influenced by diet, but
did respond to dexamethasone treatment. As the concentration of dexamethasone
increased, the expression of GLUT 4 was decreased in both dietary groups. During
early neonatal life GLUT 4 becomes the main glucose transporter, and is activated in
response to insulin stimulation (Huang et al., 2007). GLUT 4 expression is also known
to be decreased during hypertrophy (Liao et al., 2002, Santalucia et al., 2004).
Dexamethasone treatment resulted in the cultures expressing less GLUT 4, consistent
with the idea that hypertrophy was occurring in these cultures. If cultures were grown
for longer, increased expression may have been seen, because as cardiomyocytes
mature, GLUT 4 may begin to be the main regulator of glucose uptake. The transition
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from GLUT 1 to 4 becoming the main glucose transporter occurs during early postnatal
life (Huang et al., 2007), therefore in this current study cultures may not have
reached the time of transition.
Looking at glucose transporter expression in relation to the insulin stimulated glucose
uptake in day 2 cultures, GLUT 1 was unaffected by both diet and dexamethasone.
GLUT 4 expression was decreased as dexamethasone concentration increased, but did
not respond to maternal diet. It was expected that GLUT 4 expression would be
increased with MLP diet and dexamethasone treatment, as it is the transporter which
mediates uptake in response to insulin. Insulin signals lead to translocation of GLUT 4
to the plasma membrane permitting uptake of glucose into the cell (Shaohui et al.,
2007, Watson et al., 2004). The reason for a decrease in expression could be because
there was no insulin present in the cultures measured for GLUT 4. However, in the
glucose uptake assay cells were incubated with insulin for 30 minutes. It would be
interesting to investigate protein expression of the glucose transporters by western
blot as there may be a difference in functional protein concentrations, which cannot be
observed at the mRNA level.
From these findings glucose transporters may be ruled out as the mechanism
underpinning the observed increase in insulin stimulated glucose uptake. Neither GLUT
1 nor 4 showed an increased sensitivity to dexamethasone due to maternal low
protein diet. Future studies could investigate the effects of MLP diet in utero and
glucocorticoids in culture on the insulin receptor or components of the insulin-
signalling pathway, as insulin is the primary component that stimulates glucose uptake
in the cell.
Ozanne et al. (1997, 2006) have investigated a panel of insulin signalling proteins in
both rat and human adipose tissue. There are various components that make up the
insulin signalling pathway and a few have been identified as important in determining
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glucose transport and insulin resistance. These include insulin receptor susbstrate-1
(IRS-1) and protein-kinase C-ǅ 3&.ǅ DOVR NQRZQ DV 35.&= WKRXJKW WR SOD\ DQ
important role in mediating the action of insulin to stimulate glucose uptake. Two
subunits of phosphatidylinositol (PI) 3-kinase, the regulatory subunit, P85Į, and the
catalytic subunit, P110ǃ, are crucial in many metabolic activities of insulin, and are
markers of insulin resistance. (Ozanne et al., 1997, Fernandez-Twinn et al., 2004,
Ozanne et al., 2006).
Ozanne et al. (2006) found that adult male humans of low birth weight had reduced
GLUT 4, p85Į subunit, P110 ǃ subunit and IRS-1 protein concentrations. There was no
change in IR protein levels or mRNA levels. In rats fed MLP, adipocytes from three
month old male offspring exhibited significantly higher basal and insulin-stimulated
glucose uptake (Ozanne et al., 1997). This was thought to be linked to a three-fold
increase in insulin receptors, thereby altering glucose transport. They also showed an
increase in IRS-1 associated and p85 associated PI3-kinase activity, all key
components in the insulin signalling pathway (Ozanne et al., 1997). In a similar study
by Fernandez-Twinn et al. (2004), twenty-one month old rats displayed a decrease in
3&.ǅH[SUHVVLRQ LQPXVFOHDQGSǃDVVRFLDWHGSĮH[SUHVVLRQ LQDEGRPLQDO IDW
These are downstream effects of IR in peripheral tissues and potentially markers for
insulin resistance. Further investigation of the expression of these proteins in
cardiomyocytes may be necessary to determine the mechanisms by which MLP and
dexamethasone impact upon glucose uptake.
As the glucocorticoid receptor is the main receptor for glucocorticoids to bind to (Cole
et al., 1995), alteration in its expression could have lasting effects on GC regulation
and sensitivity, and blood pressure (Lillycrop et al., 2005). It was hypothesised in this
study that GR expression would be programmed in offspring exposed to maternal
protein restriction. Diet had no impact on the expression at either time point, which
did not support the hypothesis. This also disagrees with evidence that suggests that
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the MLP diet increases expression of GR in various tissues. Lillycrop et al. (2005)
found that MLP diet fed during gestation increased GR methylation status in the
offsprings liver at weaning. Langley-Evans et al. (1996) noted an increased GR
binding capacity and receptor numbers in the hippocampus in offspring from protein
deficient mothers, resulting in permanent alterations in the HPA axis. GR protein and
mRNA expression was also increased in the peripheral tissues including kidney, liver
and lung of MLP offspring (Bertram et al., 2001). This was 2-fold higher in MLP
compared to control in fetal and neonatal life, which increased in adult life to a 3-fold
increase. Conversely, GR expression was decreased in the hypothalamus, and
comparable to this study, no alteration of GR expression was found in the hearts of
these offspring (Bertram et al., 2001). The increase in peripheral tissue GR expression
is likely to result in increased sensitivity of specific tissues to GCs, and decreased
sensitivity in central tissues, which exhibits a decrease in expression.
Possible suggested mechanisms for altered GR and other glucocorticoid regulating
receptors, such as MR, include the suggestion that MLP causes a decrease in the
expression of 11ǃ-HSD-2. This enzyme, prominent in feto-placental tissue, converts
active GCs to an inert form as they pass from mother to fetus (Benediktsson et al.,
1993). A decrease in 11ǃ-HSD-2 results in overexposure of the fetus to maternal GCs,
which leads to increased sensitivity of the offspring to circulating glucocorticoids
(Langley-Evans et al., 1996). There are several reasons as to why MLP had no effect
on the cardiomyocyte cultures in this study. As discussed, the heart is not a tissue
where GR is influenced by MLP diet. It appears that GR is more abundantly expressed
in tissues such as the liver and kidney than the heart. The heart is also not a major GC
target tissue because of low expression of receptors. There is also a possibility that
any in vivo effect of MLP has been lost after 10-12 days in culture.
Cultures treated with 100nM of dexamethasone had a higher expression of GR in
comparison to untreated cells, while 10nM dexamethasone treated cells showed
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intermediate expression. As GR is the main glucocorticoid receptor it was expected
that its expression would be increased with dexamethasone treatment. This indicates
that the cultures are responsive to glucocorticoids and are functioning as they would in
vivo. Nyirenda et al. (1998) found administering dexamethasone to pregnant rats in
the last week of pregnancy led to an increased expression of hepatic glucocorticoid
receptor, but attenuated GR expression in hippocampal nuclei that mediate the HPA
axis. Interestingly, when Dex was administered at any other time points in pregnancy
it had no effect, demonstrating that GCs have specific effects at different time points
of development. This suggests that GR expression is down-regulated in response to
glucocorticoids in certain tissues and up-regulated in others.
In summary, the main findings from this study were that diet had no effect on
maternal food intake, weight or litter size. Binucleation was considerably lower than
mononucleated cardiomyocytes in both trials, indicating that all cultures were actively
proliferating. Baseline binucleation was no different between dietary groups in either
trial. Day 2 MLP cultures in trial one, however had an increased incidence of
binucleated cardiomyocytes, suggesting that low protein diet increased the number of
fully differentiated cardiomyocytes. The protein:live cell count ratio suggested that
MLP diet decreased the size of cells in day 2 treated cultures, but increased in day 2
untreated, even though dexamethasone did not have a significant impact. High
concentrations of dexamethasone increased insulin stimulated glucose uptake in
neonatal cardiomyocytes, but glucose uptake transporters were not identified to be
the mechanism behind this. Maternal low protein diet had no impact on GLUT 1, 4 or
GR mRNA expression at the baseline level, but dexamethasone treatment decreased
expression of GLUT 4 mRNA and increased expression of GR. These findings are
consistent with in vivo work indicating that cultures show changes in structure and
function of neonatal cardiomyocytes.
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There were various limitations to this study, some discussed throughout this thesis.
Cell counting was a crude method susceptible to human error. Future studies might
want to explore different methods of cell counting that could give more replicates in
order to gain the more accurate counts. De Vries et al. (2002) and Corstius et al.
(2005), measured cell and nuclei number using histological techniques in heart tissue.
It would also be interesting to measure neonatal ventricle wall and septum thickness,
and chamber size to assess hypertrophy. As the baseline DNA content of the
cardiomyocytes fell below the detection limit in the fluorescence method used in this
study, using the bromodeoxyuridine (BrdU) cell proliferation method may be more
sensitive to small amounts of DNA. One of the main lines of investigation for further
study, as mentioned previously, would be to measure the expression of other genes
and proteins involved in insulin stimulated glucose uptake, and to further explore MLP
cultures sensitivity to administration of glucocorticoids neonatally.
It would also be interesting to grow cardiomyocytes for longer periods of time to
investigate if hypertrophic-like cell characteristics continue in MLP cultures, and if
there are windows of increased sensitivity to glucocorticoids. Also culturing cells for a
shorter amount of time could highlight if effects of MLP that may be lost over time as
cultures multiply. Cardiomyocytes could also be treated with other hormones, such as
insulin, to monitor their effects and examine if MLP diet impacts on the cultures
responses.
4.4 Conclusion
Cell proliferation and differentiation measures, glucose uptake and mRNA expression
possibly indicate hypertrophic growth occurring prematurely in MLP cultures compared
to control. Findings however, were not consistent enough across the two trials to
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conclude this and will need further investigation to clarify. Findings from this study
were varied so cannot fully support the work of Cheema et al. (2005), Tappia et al.
(2005), Corstius et al. (2005) who concluded that MLP diet during gestation leads to
remodelling of heart tissue, which is a precursor to the later onset of CVD. Clarification
of the effects of MLP diet on heart remodelling is needed with further animal studies
and optimisation of cardiomyocyte cultures. It is more likely that effects seen from
MLP diet on the cardiomyocytes are due to glucocorticoid overexposure during fetal
development.
The primary aim was to establish if cultured cells retain memory of fetal diet. To some
extent cardiomyocytes replicated findings from in vivo studies, but it is difficult to
interpret if cardiomyocytes retain memory of maternal undernutrition as findings were
not consistent across trials. Many of the effects seen in offspring due to undernutrition
during gestation are reliant on whole body integration of physiological and endocrine
signals. In the case of hypertension and reduced nephron number it has been
suggested that one impacts on the other causing a cycle to develop (Mackenzie et al.
(1995), discussed in Harrison et al. (2008)). This effect would not be seen in culture.
The replacement, refinement and reduction of animals in biological research is a high
priority from an ethical perspective. The development of alternatives to in vivo studies
for the investigation of fetal programming was one of the hoped outcomes for this
study, as cultures would allow for reduction of animal use. It is unlikely though that
cell culture will become a viable alternative model to animals for the further
investigation of fetal programming, but it is proving to be a useful tool for exploring
focused mechanisms. This study has led to new paths of exploration into the
mechanisms that underpin heart remodelling, and partially supported current findings,
demonstrating the potential of using cell culture in the investigation of fetal
programming.
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6 Appendix
Cell Culture Reagents
Medium Solution for growing Cardiomyocytes
500ml DMEM plus 50ml of fetal bovine serum, 5ml of Fungizone, and 5ml of penicillin-
streptomycin. This was aliquoted and frozen at -20°C.
The following reagents were provided in the Worthington Neonatal Cardiomyocyte
Isolation System kit.
Leibovitz L15 Medium
The sachet of medium was dissolved in 1 litre of autoclaved distilled water and filtered
into sterile containers.
Trypsin (Vial #2)
Vial #2 was dissolved in 2ml CM-HBSS on ice.
Trypsin Inhibitor (Vial #3)
Vial #3 was dissolved in 1ml of CM-HBSS at room temperature.
Collegenase (Vial #4)
Vial #4 was dissolved in 5ml of filtered L15 medium at room temperature.
Dexamethasone
Stock Soultion: 39.2mg dissolved in 1ml of ethanol (100mM).
Working Soultions: 1µM: 5ml of 100µM solution dissolved in 500ml DMEM.
10nM: 1ml of 1µM solution dissolved in 100ml DMEM.
100nM: 50ul of 100µM solution dissolved in 50ml DMEM.
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Endpoint Measurements Reagents
PBS
Stock (10x): 40g NaCl, 1g KCl, 7.2g Na2HPO4, 1.2g KH2PO4 in 500ml dH20.
Working (1x):100ml of 10x PBS solution plus 900ml dH20.
Autoclaved.
Staining Cardiomyocytes
1mg/ml solution of Bisbenzamide H3385 (Hoechst stain) dissolved in dH20.
Cell Lysis Buffer for DNA and Bradford Assay
10mM Imidazole pH7.3, 0.5M NaCl, 1% Triton X-100, 2mM Sodium Azide, 0.2mM
Sodium Ortho-vanadate, 0.2mM PMSF dissolved in 1 litre of distilled water, aliquoted
and stored at -20°C.
Determination of Protein Content
Reagent: Dissolved 40mg of Coomassie Brilliant Blue (Sigma, UK) in 20ml
Phosphoric Acid (FLUKA, UK) then added 40ml ethanol (Fisher Scientific, UK) made up
to 500ml with distilled water (440ml) and mixed thoroughly. Solution was stored in
the dark for 2 weeks to mature and remained stable for 2 months.
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DNA Assay
10x TNE buffer: 10mM Tris HCl, 1mM EDTA, and 200mM NaCl in 100ml of dH20.
2x TNE buffer: 1:5 dilution of 10x TNE with dH20.
Bisbenzimide H33258 Dye
Stock: 1mg/ml with dH20
Working: 15ǋl of 1mg/ml stock dye plus 15ml of 2x TNE. Protect from the light.
Cell Death Kit
Reagent 1 Antihistone Biotin  Reconstituted in 450ǋl double distilled water for 10
minutes.
Reagent 2 Anti-DNA POD - Reconstituted in 450ǋl double distilled water for 10
minutes.
Reagent 3 Positive Control - Reconstituted in 450ǋl double distilled water for 10
minutes.
Immunoreagent For 10 tests  720ǋl Incuation buffer, 40ǋl Reagent 1, 40ǋl
Reagent 2.
Incubation buffer Background control.
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Liver Homogenate for QC for Cell Death, DNA and Protein assays
DNA
Tissue (approximately 100mg) was homogenised in 1ml of cell lysis buffer, then
aliquoted and frozen at -20°C.
Protein
Tissue (approximately 100mg) was homogenised in 1ml of cell lysis buffer, and diluted
1:20 with dH20, then aliquoted and frozen at -20°C.
Cell Death
Tissue (approximately 100mg) was homogenised in 1ml of lysis buffer provided in the
kit, and diluted 1:20 with dH20, then aliquoted and frozen at -20°C.
Glucose Uptake Assay
Insulin
Stock: 10mg insulin dissolved in 1ml 1x PBS (1.73mM). Stored at 4ºC.
Working: 1µl insulin stock in 9ml 1x PBS. Made fresh daily.
2-deoxyglucose (2-dG)
Stock: 1g dissolved in 60ml of 1x PBS. Stored at 4ºC.
Working: 10µl stock 2dG in 10ml of 1x PBS (1:1000 dilution). Made fresh daily.
H3-2-DG Solution: 10µl H3-2-DG, 10µl working 2dG, 10ml 1x PBS. Made fresh daily.
Specific activity, 1.0TBq/mmol.
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RNA extraction using the Qiagen RNeasy Mini Kit
70% ethanol was prepared using standard laboratory ethanol (Fisher Scientific, UK)
and RNase free water (Sigma, UK).
10µl E-mercaptoethanol per 1ml Buffer RLT was prepared fresh daily.
Buffer RPE - Added 4 volumes of ethanol (Fisher Scientfic, UK) on first use of the kit.
DNase Treatment Step
DNase l stock solution  Dissolved lyophilized DNase l in 550µl RNase free water
(provided in the kit).
DNase incubation mix - 10µl of DNase l stock solution plus 70µl Buffer RDD per
sample.
